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Abstract 
Mechanisms underlying the chemopreventive effect of celecoxib in gastric 
carcinogenesis 
Gastric cancer (GC) is the second leading cause of cancer related death worldwide. 
To date, there is no effective measure to prevent gastric cancer development. 
Celecoxib, a COX-2 inhibitor, has been shown to reduce polyp formation in a 
cohort of patients with familial adenomatous polyposis syndrome. 
N-methy-N' -nitro-N- nitrosoguanidine (MNNG) induced gastric cancer in rats is 
widely used as model for differentiated-type human stomach carcinomas. 
Previously, we showed that treatment with celecoxib suppressed MNNG induced 
gastric cancer in rats and celecoxib is shown to have inhibitory effect on gastric 
tumors growth in rat. We used microarray to analyze four groups of samples: (1) 
MNNG-induced rat gastric tumors (T), (2) its adjacent normal tissues (N), (3) 
celecoxib treated, MNNG- induced rat gastric tumors (CT) and (4) its adjacent 
normal tissues (CN). 
75 and 283 genes were found to be up- and down-regulated respectively in the 
v i i 
MNNG-induced tumors by 2-fold criterion as compared with the adjacent normal 
tissues. Up-regulated genes included those involved in ion binding, cell adhesion 
and glutathione transferase activity. The down-regulated genes were related to 
DNA binding, rhodopsin-like receptor and G-protein couple receptor activity. 
When comparing the celecoxib treated rat gastric tumors with the adjacent normal 
tissues, 320 and 619 genes were up- and down-regulated respectively, by 2-fold 
criterion. To elucidate the mechanisms underlying the chemopreventive effects of 
celecoxib, analysis was also performed to identify genes with the two expression 
trends: T>CT〉N>CN (down-regulated by celecoxib) and CN>N>CT>T 
(up-regulated by celecoxib). 197 and 199 genes were found to be altered in these 
two patterns, respectively. In the T>CT>N>CN trend, genes were related to 
transporter activity, protein kinase activity and catalytic activity. Genes involved 
in magnesium ion binding and protein kinase activity were found in the 
CN>N>CT〉T trend. Eight genes were selected for verification by quantitative 
RT-PCR in rat gastric tissues and in human gastric cancer cell line M K N 45. 
Among these altered genes, the expression of Aktl was found to be significantly 
down-regulated by celecoxib treatment. The Akt gene plays important roles in 
various cell survival pathways leading to apoptosis and survival. We further 
vi i i 
showed that the protein expressions of phospho-Akt and phospho-PDKl were 
suppressed by celecoxib treatment while the protein expression of phospho-PTEN 
remained unchanged. In addition to demonstrating the chemopreventive effect of 
celecoxib in gastric carcinogenesis, we have identified other potential non-COX 
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Chapter 1 
Introduction 
1.1 Epidemiology of gastric cancer 
In the 1930s, gastric cancer was the most common cause of cancer death in 
America and Europe. During the following 70 years, mortality rates have fallen 
dramatically in most developed countries. However, in the past 30 years, the 
incidence of gastric cancer rose again[l]. Although the mortality rate of gastric 
cancer has markedly declined around the world, it is still rising in Asian countries 
[2, 3].Gastric cancer is now the second major cause of cancer death in the world. 
Men are at higher risk to develop gastric cancer. The male-to-female ratio of 
gastric cancer is approximately 2:1. In addition, the risk of gastric cancer 
increases with ages, with a peak incidence between 50 and 70 years[l]. 
Gastric cancer incidence vary by up to ten-fold in different countries. Nearly 
two-thirds of stomach cancers occur in developing countries. Japan, Korea and 
China have the highest gastric cancer rates in the world[4]. Other high gastric 
cancer incidence areas include East Asia, Eastern Europe, and Central and South 
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America. Low incidence rates are found in South Asia, North and East Africa, 
North America, Australia, and New Zealand [1]. (Figure 1 and 2) 
In Hong Kong, both the gastric cancer incidence and mortality rates of male and 
female are decreasing from 1983 to 2003 (Figure 3). The incidence and mortality 
rates of men were about 2 fold higher than those of women. The risk to have 
gastric cancer increases with ages. The incidence of gastric cancer is higher in 
older people (Figure 4). 
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Figure 1. Geographical distribution of gastric cancer incidences in men. 
(The International Agency for Research on Cancer) 
- 3 -
stomach. Females 
Crude incidence rate per 100,000 
X ~ 、〜 
• < 2 ,2 • < 4.5 < 7.9 • < 12,8 • < 5 5 . 4 
GLOBOCAN 2002, lARC 
Figure 2. Geographical distribution of gastric cancer incidences in women. 
(The International Agency for Research on Cancer) 
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Gastric Cancer Incidence and Mortality Rates in Hong Kong 
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Figure 3. Both the incidence and mortality rates of male and female are 
decreasing in recent years. 
(Hong Kong Cancer Registry) 
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Gastric cancer incidences in different age group in Hong Kong 1983 -
2003 
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Figure 4, The incidences of gastric cancer are increasing with ages. 
(Hong Kong Cancer Registry) 
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1.2 Risk factors associated with gastric cancer 
There are various risk factors associated with gastric cancer. One of the major 
factors is Helicobacter pylori infection. In 1994, the International Agency for 
Research on Cancer classified H. pylori as a type I carcinogen in human[5]. H. 
pylori is a gram-negative bacillus that colonizes the human stomach which can 
cause chronic gastritis and gastric cancer [6]. Several studies support the 
association between H. pylori infection and gastric cancer risk[7, 8]. 
The other factor associated with gastric cancer is diet. There are evidences that 
consumption of salty foods and A^-nitroso compounds induce gastric cancer. 
Moreover, lack of fresh fruits and vegetables in diet increases the risk of gastric 
cancer. Salt has been proved to cause gastritis and enhanced the risk of gastric 
cancer development in animal model[9]. Intake of salted food may increase the 
risk of H. pylori infection and promote the development of gastric cancer[l]. 
A^-nitroso compounds, such as A^-methyl-7V '-nitro-A^- nitrosoguanidine (MNNG), 
are carcinogenic in animal models [10]. MNNG may induce carcinogenesis by 
hydroxyl free radical ( -0H) production[l l ]. Some studies have reported 
significant reductions in gastric cancer risk by fruit and vegetable consumption 
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because of their high content in antioxidant vitamins and polyphenols [12]. 
Smoking is another risk factor related to gastric cancer. For cigarette smokers, the 
risk to develop gastric cancer is about 2 fold higher than non-smokers[13]. Other 
tobacco products such as cigar and pipe also increase the risk of gastric 
cancer[14]. Tobacco products contain a lot of carcinogens. These carcinogens can 
bind to gastric mucosal DNA[15]. In addition, smoking may stimulate gastric acid 
and pepsin secretion, which may cause gastric mucosal injury and promote 
stomach carcinogenesis [16]. 
Obesity can enhance the risk to develop gastric cancer. Body mass index (BMI, 
expressed in kg/m^) is commonly used to measure adiposity. When using a cutoff 
value of BMI> 30, the risk to have gastric cancer increases to 16-fold compared 
with persons with B M I < 22[17]. The association between obesity and gastric 
cancer development is unclear, but is probably related to gastroesophageal reflux 
and development of cardia cancer. Some studies suggest that higher B M I 
increases gastroesophageal reflux due to higher abdominal pressure[ 18-20]. 
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1.3 Prevention of Gastric Cancer 
The prognosis of gastric cancer is generally poor and the main strategy for 
improving clinical outcomes of gastric cancer is through early detection and 
prevention. The mortality rate from gastric cancer has remained static since the 
early 1970s[l]. Endoscopy can be used to diagnose early gastric cancer. About 
half of gastric tumors can be detected at an early stage in asymptomatic 
individuals. In Japan, there is a surveillance program which recommends annual 
screening with a double-contrast barium technique or endoscopy for persons aged 
over 40[21]. 
Lifestyle modifications help to reduce the risk of gastric cancer. Reduced tobacco 
smoking, high salt and nitrite food consumption and increase fruit and vegetable 
intake can prevent gastric cancer[l]. The invention of electric refrigerator led to a 
decrease in the intake of chemically preserved foods and increased consumption 
of fresh fruits and vegetable, which may explain the decline of gastric cancer 
incidence and mortality rates in recent years[22]. 
Antioxidants such as vitamins C and E may have a protective effect on the risk of 
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gastric cancer. They are important antioxidant which may inhibit carcinogenesis in 
the stomach by neutralizing reactive oxygen species that can damage DNA[23]. In 
addition, vitamins C and E can prevent gastric carcinogenesis by inhibiting the 
formation of carcinogenic nitrosamines[24]. 
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1.4 H. pylori eradication and gastric cancer development 
There is a strong relationship between H. pylori infection and gastric cancer. 
However, there is paucity of data showing that treatment of H. pylori infection 
could prevent cancer as it takes a very long time to develop gastric cancer. 
Moreover, conclusive proof for the preventive effect of H. pylori eradication on 
gastric carcinogenesis wi l l never be available as it requires the use of a placebo 
control group which may have ethical issue[25]. A more practical approach to 
measure the effects of eradication of H. pylori is to examine the regression of 
precancerous changes such as intestinal metaplasia (IM) and glandular atrophy 
(GA) of the stomach[26]. 
The effective treatment against H. pylori is antibiotic. One week triple-therapy of 
omeprazole, amoxicillin and clarithromycin (OAC) are commonly used to 
eradicate H. pylori[26]. For penicillin-sensitive patients, metronidazole is used to 
replace amoxicillin. Unfortunately, an increasing number of H. pylori strains are 
found to be resistant against the first-line antibiotics[27], A randomized study 
conducted in China showed that eradication of H. pylori was significantly 
associated with a decrease in the risk of I M progression. Patients assigned to 
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receive OAC had a significantly lower risk of progression compared with those 
who received placebo[26]. Another prospective, randomized, placebo-controlled 
study in Fujian Province of China [28] showed that eradication of H. pylori 
significantly decreased the development of gastric cancer in H. pylori carriers 
without precancerous lesions. 
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1.5 Non-steroidal anti-inflammatory drugs and gastric cancer prevention 
Another promising approach to reduce the risk of cancer is through 
chemoprevention [29]. Non-steroidal anti-inflammatory drugs (NSAIDs) such as 
aspirin has been shown to reduce the risk of gastric cancer development in 
epidemiological studies [30-32]. However, the mechanism of the anticancer 
properties of NSAIDs is still not very clear. Increasing amount of evidences show 
that NSAIDs exert their anti-neoplastic effect by inhibition of cyclooxygenase 
(COX) and prostaglandin [33]. COX enzyme can catalyze the conversion of 
arachidonic acid into prostaglandin E2[34]. There are two isoforms of COX 
enzyme. COX-1 is expressed constitutively whereas COX-2 is an inducible 
enzyme. Notably, overexpression of COX-2 is frequently detected [35, 36]. 
COX-2 overexpression was detected in patients with H. pylori infection[37]. 
Several studies in colonic cancer show that induction of COX-2 can result in 
inhibition of apoptosis, increase in angiogenesis, and metastatic potential [38]. 
Furthermore, COX-2 expression in the antral mucosa was shown to be reduced in 
the epithelium after successful eradication of H.pylori[l>9]. 
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1.6 COX-2 independent pathway 
Recent reports suggest that NSAIDs exert their anti-neoplastic effects through 
COX independent pathway [40-42]. Some agents such as sulindac sulfone that has 
no COX-2 inhibitory effect could also inhibit colorectal carcinogenesis in animal 
model [43]. And the use of low dose aspirin, which do not inhibit COX-2, could 
reduce colorectal adenoma development [44]. As a result, NSAIDs are believed to 
exert their anti-neoplastic effects through COX-independent pathways. 
Celecoxib, a COX-2 specific inhibitor, initially developed for the treatment of 
adult rheumatoid arthritis and osteoarthritis. Also it has been used to reduce polyp 
formation in a randomized, placebo-controlled trial in patients with familial 
adenomatous polyposis syndrome [45]. We have previously shown that treatment 
with celecoxib (specific COX-2 inhibitor), but not indomethacin (non-selective 
COX inhibitor), beginning shortly after carcinogen administration inhibited the 
growth and development of gastric tumors in rat [46]. The lowest COX-2 and 
prostaglandin E2 levels were found in indomethacin-treated group, rather than in 
celecoxib treated group, suggesting that the chemopreventive effect of celecoxib 
may be mediated by a COX-2 independent pathway. 
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1.7 Animal model of gastric cancer 
To examine the anti-cancer effect, an animal model is useful. During the 1960s, 
A^-methyl-A/^'-nitro-A^-nitrosoguanidine (MNNG) was widely used to produce 
mutations for microbiological genetic studies. Its subcutaneous injection 
effectively yielded fibrosarcomas in rats[47]. Subsequently, M N N G was dissolved 
in water and given to rats as a drinking water solution and adenocarcinomas were 
found in the glandular stomach[10]. iV-methyl-iV，-nitro-A^- nitrosoguanidine 
(MNNG) induced gastric cancer in rats is widely used as model for 
differentiated-type human stomach carcinomas [10]. 
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1.8 Microarray system 
Microarrays are powerful tools to screen for changes in gene expression following 
drug treatments either in cell lines or in tissues following treatment. Thus 
microarrays can be used to screen for large amounts of chemical for drug 
development. The expression profiles can provide information on the mechanism 
or the pathways affected by drugs. Moreover, some components of those 
pathways may be chosen for markers of drug response. 
There is much advancement in microarray technologies. Microarray is first 
performed by using Filter arrays[48]. Filter arrays are made by spotting DNA or 
RNA samples on nylon membranes. The advantages of Filter arrays are that they 
are commercially available and require no specialized equipment. 
Glass DNA microarrays are the second generation microarray. They are produced 
by the robotic application of DNA to a glass surface[49]. Glass is a material 
which is transparent and rigid. These properties improve image acquisition and 
sensitivity. As the target or test samples are labeled by fluorescent dye, several 
targets can be hybridized simultaneously in a single reaction, allowing direct 
- 1 6 -
comparison between samples[50]. 
The third generation of microarray is High-density oligonucleotide arrays. 
Oligonucleotides are synthesized in situ on a flat solid support[51]t. Affymetrix 
developed a method to attach linkers containing a photochemically removable 
protecting group to the glass surface. Then selected areas of the surface are 
activated by illumination through a photolithographic mask, yielding reactive 
hydroxyl groups. A given nucleotide (A, G, C or T) is incubated with the surface 
under conditions that allow attachment of a single nucleotide only to the areas that 
have been illuminated. Repeating this process by a series of photolithographic 
masks allows the synthesis of a large number of distinct oligonucleotides[52]. The 
advantages of this approach are the usage of glass and much higher densities of 
probe can be used in the glass support. 
In this study, we attempt to elucidate the anti-tumor mechanisms of celecoxib by 
first examining the gene expression profile of the MNNG induced gastric cancer 
in rats and compared against celecoxib treated rats. The microarray data was then 
confirmed in human gastric cancer cell. Moreover, potential non-COX dependent 
pathway was identified through the microarray analysis. 
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1.9 Hypothesis 
1. Celecoxib inhibits gastric cancer development in rat 
2. The chemopreventive effect of celecoxib is mediated by COX-independent 
pathway. 
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1.10 Aim of study 
This study examines the anti-tumor mechanisms of celecoxib by examining the 
gene expression profiles of the MNNG induced gastric cancer in rats. Moreover, 
investigation was performed to find out the role of other non-COX dependent 
pathway in chemoprevention of gastric cancer. 
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Chapter 2 
Chemoprevention of gastric cancer by celecoxib 
2.1 Introduction 
Long term use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) has 
been shown to reduce the risk of colorectal cancer[43]. Moreover, celecoxib, a 
COX-2 inhibitor, has been shown to reduce polyp formation in patients with 
familial adenomatous polyposis syndrome[45]. Apart from colorectal cancer, 
COX-2 is frequently expressed in gastric cancer as well as in premalignant gastric 
lesions [3 5]. There are in vitro data to suggest that inhibition of COX-2 suppress 
the growth of gastric cancer cells. Furthermore, the use of COX-2 inhibitors has 
been shown to suppress the growth of gastric cancer xenografts in nude mice. 
However, unlike colorectal cancers, there is paucity of data on the effectiveness of 
COX-2 inhibition in the prevention of gastric cancer. In this study, we evaluated 
the use of celecoxib in the prevention of A^-methyl-A/''-nitro-A^-nitrosoguanidine 
(MNNG) induced gastric cancer in rats. 
- 2 0 -
We also investigated the anti-cancer effect of celecoxib in human gastric cancer 
cells. Human gastric epithelial cancer cell line M K N 45 (ATCC, Manassas, VA, 
USA) were used to study the changes in growth rate and gene expression in 
response to the treatment of celecoxib. M K N 45 was established in Japan from a 
62 years old female patient. This cell line is a poorly differentiated 
adenocarcinoma, which was metastasized to gastric from liver[53]. There are 
some alterations in tumor suppressor genes in M K N 45. This cell line has 
wild-type p53 and high expression level of p21 mRNA[54]. In addition, there are 
alterations in oncogenes in M K N 45. There is no amplification of c-erb^2 gene 
and lower expression level of Bcl-2[52>]. M K N 45 also expresses cytokine IL-8 
and growth factors platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF)[55]. For the cell 
adhesion molecule genes, there is an 18bp deletion in the boundary between the 
6th exon and intron of E-cadherin gene[56]. M K N 45 was used in our study 
because of its high growth rate. Moreover, M K N 45 is an adhesive cell line. It can 
be handled easily as there were multiple washing steps after the treatment of 
celecoxib. 
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2.2 Material and Methods 
2.2.1 Animals 
The rat MNNG induced gastric cancer model was adopted [10]. Eighty-six 
four-week-old grade 2 male Wistar rats, approximately 50 g in weight, were 
obtained from the Laboratory Animal Centre of the Sun Yat-Sen University. The 
living environment of rats was 21°C, humidity 50%, with a 12 hour light-dark 
cycle. Rats had free access to regular chow pellets and drinking water. There was 
one acclimatization week before starting this experiment. The study protocol was 
approved by the animal ethics committee of the Sun Yat-Sen University. 
2.2.2 Chemicals 
100 |ig/ml MNNG (Fluka, Germany) was prepared in distilled water three times 
per week. The MNNG solution was protected from light and given ad libitum to 
rats through the drinking water. In addition to MNNG, 1 ml of 10% sodium 
chloride was given to rats weekly by oral gavage in the first six weeks to enhance 
the development of gastric cancer [9]. 
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2.2.3 Study design 
Rats were divided into two groups (group A and group B). Group A was treated 
with MNNG only. Group B was treated with celecoxib (Pfizer Pharmaceuticals, 
New York) at 20 mg/kg/day by oral gavage given daily from the age of six weeks 
for 40 weeks in addition to MNNG. Group C was control rats not treated with 
celecoxib or MNNG. A l l rats were monitored for general health during the study 
period. The body weights of rats were recorded weekly. After 48-week, all rats 
were sacrificed. Rats that died before week 48 were autopsied to find out the 
cause of death and presence of gastric tumors. At laparotomy, the stomach was 
opened along the greater curvature and was examined carefully, as were other 
organs. A l l dissections were performed by investigators blinded to treatment 
allocation [57]. Tumor incidence (percentage of animals with tumor development) 
and tumor multiplicity (mean number of tumors per animal) were compared 
among animals fed MNNG and celecoxib. Non-parametric data were computed by 
chi square test and t-test. A p value of <0.05 was considered to be statistically 
significant. 
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2.2.4 Cell Culture 
Human gastric epithelial cancer cell line M K N 45 (ATCC，Manassas, VA, USA) 
were retrieved from liquid nitrogen and were dispersed with 10 ml RPMI 1640 
medium containing 10% fetal bovine serum (FBS) (JRH Biosciences, KS, USA), 
1% penicillin-streptomycin (PS) (Gibco, NY, USA) in 75 cm culture flasks 
(Coming Incorporated, Corning, NY, USA). Cells were maintained in and grown 
in humidified 5% CO2 atmosphere at 37°C. When the cells reached 70% to 80% 
confluent, they were sub-cultured by washing with phosphate-buffered saline 
(PBS) (Amresco, Solon, OH, USA). Trypsin (Gibco, NY, USA) was added to 
detach the cells from the culture flasks. RPMI 1640 medium with 5% FBS and 1% 
PS were added to neutralize the trypsin. Excessive number of cells could be 
reduced by discarding the culture medium containing cells. 
2.2.5 Celecoxib treatment 
Celecoxib (Pfizer Pharmaceuticals, New York) was used in this experiment. A 25 
m M stock solution was made by dissolving 200 mg celecoxib in 20 ml DMSO. 
Further dilutions were made by using the stock solution and the RPMI 1640 
medium with 5% FBS and 1% PS. M K N 45 cells at 80% confluent were 
harvested by trypsinization and 1x10^ cells were seeded in each well of 6-well 
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plate (Corning Incorporated, Corning, NY, USA). Drug treatment was started after 
the cells had left to seed on the bottom of the plate for 24 hours. Cells were 
treated with various concentrations of celecoxib (0 | iM, 10 [iM, 20 |j,M, 50 |j.M, 
100 |j,M and 200 |iM) for 24 hours. After the drug treatments, they were washed 
by phosphate-buffered saline (PBS) (Amresco, Solon, OH, USA). 
2.2.6 Cell proliferation assay 
M K N 45 cells were seeded at a density of 2.5x10^ in each well of 6-well plate 
(Corning Incorporated, Corning, NY, USA). The effect of celecoxib in inhibiting 
the cell proliferation of human gastric epithelial cancer cell line, M K N 45, was 
determined by Trypan blue staining assay. Trypan blue is an acidic diazo dye 
which is used to measure cell viability. Since cell membrane is highly selective, 
trypan blue is not absorbed in viable cell but it traverses the membrane in a dead 
cell. Hence, dead cells are shown as a distinctive blue color under a microscope. 
Trypsin (Gibco, NY, USA) was added to detach the cells from the culture flasks. 
RPMI1640 medium with 5% FBS and 1% PS were added to neutralize the trypsin. 
Then cells were collected as pellets by centrifuging at 1,100 rpm for 10 min at 
room temperature. The pellets were resuspened by 10 ml RPMI 1640 medium. 
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The cell number was counted by mixing 10 |il cell suspension + 10 |a.l Trypan blue 
staining (Gibco, NY, USA). Three independent experiments were performed. 
2.3 Results 
2.3.1 Chemoprevention of gastric cancer by celecoxib in rats 
Table 1 summarizes the incidences of MNNG induced gastric tumors in three 
treatment groups. Seventy-five per cent of rats treated with MNNG developed 
gastric cancer at the end of the study period whereas none of the control rats in 
control group developed gastric tumor. Rats treated with celecoxib 20 mg/kg/day 
(celecoxib group) had a significantly lower tumor incidence (31.3%) when 
compared to MNNG group (75.0%; p = 0.05). 
In addition to tumor incidence, there was a significant difference in tumor 
multiplicity (mean number of tumors per animal) among the different treatment 
groups (Table 1). Compared with the MNNG group, rats fed with celecoxib 20 
mg/kg/day had a significantly lower tumor multiplicity (p = 0.025). 
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Group Treatment No of No of rats with gastric Mean no. of gastric cancel 
rats used tumors (%) (incidence) per rat (SD) (multiplicity) 
A M N N G alone 16 12(75.0)* 1.0(0.7)** 
B MNNG+celecoxib 16 5(31.3) 0.3 (0.5) 
20mg/kg/day 
C Control 5 0(0) 0 (0) 
Table 1. Tumor incidences and multiplicity in the different treatment groups. 
*A versus B，p=0.05 (Chi square test). * * A versus B, p=0.025 (t-test). 
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Figure 5. Macroscopic and microscopic appearance of MNNG induced gastric 
tumor in a rat. (A) Macroscopic view of MNNG induced tumor formation in the 
distal stomach of a Wistar rat. (B) Haematoxylin-eosin staining of well 
differentiated gastric adenocarcinoma in the stomach (x20). 
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2.3.2 Effects of celecoxib on growth of human gastric cancer cells 
Cells were incubated with the different concentration of celecoxib for 24 hours. 
The growth of M K N 45 is inhibited in a concentration-dependent manner as 
shown in Figure 6. When treated with 10 )iM of celecoxib, the number of viable 
cells had dropped from 1.04 x 10^ to 8.6 x 10 .^ There was no cell growth when 
treated with 200 |j,M of celecoxib. 
Effect of celecoxib on cell growth of MKN 45 cells 
160 
1 4 0 
- o 120 T 
2 100 - — — — — f 
C 0 — — — —— 
g 8 0 丄 土 
20 
Q I I 1 1 1 
C o n t r o l 1 0 | i M 2 0 | i M 5 0 ^ M 1 0 0 | x M 2 0 0 ^ i M 
Concentration of Celecoxib 
Figure 6. Celecoxib inhibited the cell proliferation in M K N 45 cells. Cells were 
incubated with the different concentration of celecoxib for 24 hours. The mean 土 
standard deviations of the data of three independent experiments are shown. 
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2.4 Discussion 
2.4.1 MNNG induced gastric cancer effectively 
MNNG was widely used to induce gastric cancer in rats as a model for 
differentiated-type human stomach carcinomas since 1960s. It can be used by 
simply dissolved in water and given to rats as a drinking water solution[58]. In 
our study, 75% of rats developed gastric cancer when treated with 100 |ig/ml 
MNNG for 40 weeks, which is similar to Abe's study[59]. Abe et al treated rats 
with MNNG in a lower concentration (83 |ig/ml) and shorter duration (32 weeks) 
and found that 78.6% of rats developed stomach cancer. In another study, Tatsuta 
et al treated rats with 100 |Lig/ml MNNG for 25 weeks and an extremely high 
cancer rate was attained (96%) [60]. Both Abe and Tatsuta treated rats with 
MNNG only without sodium chloride application, which were different from our 
study. Many studies suggested that sodium chloride could enhance gastric 
carcinogenesis [61 -63]. However, the effect of sodium chloride can be suppressed 
by high-protein diet and iron chelator[64, 65]. 
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2.4.2 Celecoxib significantly suppressed gastric carcinogenesis in rats 
COX-2 expression has been reported to be associated with gastric cancers[66]. 
However, there are very few studies that investigated the anti-tumor effect of 
celecoxib in rat gastric cancer. On the other hand, various reports showed that 
celecoxib inhibited tumor growth in rat liver, colon, prostate and mammary 
gland[67-70].In our study, celecoxib reduced the gastric tumor incidences 
significantly from 75% to 31.3% (p=0.05). 
2.4.3 Celecoxib inhibited the growth of MKN 45 in a concentration-
dependent manner 
We showed that the growth of M K N 45 was inhibited by celecoxib in a 
concentration-dependent manner. The growth of M K N 45 was completely 
suppressed when treated with 200 | iM of celecoxib. There was no other study 
examined the effect of celecoxib on M K N 45. However, the effect of celecoxib 
was evaluated in other human gastric cancer cell lines. Zheng et al demonstrated 
that celecoxib inhibited the cell proliferation and enhanced apoptosis in human 
gastric cancer cell line SGC7901/ADR significantly[71]. 
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2.4.4 Celecoxib may exert its anti-tumor property through COX independent 
pathway 
Apart from showing celecoxib suppressed the growth of nasopharyngeal cancer 
cells in dose-dependent manner, Chan et al revealed that the growth inhibitory 
effect of celecoxib was independent of COX-2 expression[72]. In his study, the 
growth of three nasopharyngeal cancer cell lines, HK-1, was completely inhibited 
after treating with celecoxib with concentration ranging from 60}iM to lOOfxM for 
70 hours. However, the mRNA and protein expressions of COX-2 were not 
affected by celecoxib. 
Some reports other than Chan et al also suggest that NSAIDs exert their 
anti-neoplastic effects through COX independent pathway [40-42]. Some agents 
such as sulindac sulfone that has no COX-2 inhibitory effect could also inhibit 
colorectal carcinogenesis in animal models [43]. And the use of low dose aspirin, 
which do not inhibit COX-2, could reduce colorectal adenoma development [44]. 
As a result, NSAIDs are believed to exert their anti-neoplastic effects through 
pathways other than COX-dependent pathway. 
Celecoxib, a COX-2 specific inhibitor, initially developed for the treatment of 
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adult rheumatoid arthritis and osteoarthritis. Also it has been used to reduce polyp 
formation in a randomized, placebo-controlled trial in patients with familial 
adenomatous polyposis syndrome [45]. We have previously shown that treatment 
with celecoxib (specific COX-2 inhibitor), but not indomethacin (non-selective 
COX inhibitor), beginning shortly after carcinogen administration inhibited the 
growth and development of gastric tumors in rat [46]. The lowest COX-2 and 
prostaglandin E2 levels were found in indomethacin-treated group, rather than in 
celecoxib treated group, suggesting that the chemopreventive effect of celecoxib 
may be mediated by a COX-2 independent pathway. 
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Chapter 3 
Gene expression profiles of celecoxib treated rat gastric tumor and human 
gastric cancer cells 
3.1 Introduction 
Celecoxib was shown to prevent the MNNG induced gastric cancer in rats [46]. In 
addition, celecoxib suppress the growth of human gastric cancer cells[73]. The 
chemopreventive effect of celecoxib is believed to be mediated by both 
COX-dependent and independent pathways[40-42]. Herein, we study the 
anti-tumor mechanisms of celecoxib by examining the gene expression profiles of 
the MNNG induced gastric cancer in rats. 
3.2 Material and Methods 
3.2.1 RNA extraction 
Gastric tumor (T) and their adjacent non-tumor tissue (N), celecoxib treated 
MNNG induced-gastric tumors (CT) and their adjacent non-tumor tissues (CN) 
were obtained for RNA extraction. Ultrasound homogenizer was used to 
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homogenize the gastric tissue. Total RNA was extracted by RNA Tri Reagents 
(CINNA/MRC; Cincinnati, OH, USA). After isolation, RNA was assessed by 
using agarose denature gel. Three pairs of samples with good RNA qualities were 
selected for the microarray analysis. 
3.2.2 Target preparation and Array hybridization 
The CodeLink cDNA expression assay kit (Amersham Biosciences, Piscataway, 
NJ, USA) was used. Two \xg of total RNA was used to synthesize cRNA. 
First-strand cDNA was reverse transcripted from the total RNA using reverse 
transcriptase and a T7 primer. Then the complementary second-strand cDNA was 
generated using DNA polymerase mix and RNase H. The double-stranded cDNA 
was purified by GFX PGR DNA and Gel Purification Kit (Amersham Biosciences, 
UK). cRNA was generated via an in vitro transcription reaction using T7 enzyme 
mix and biotin-11-UTP (Perkin-Elmer, Boston, MA, USA). cRNA was purified by 
RNeasy Min i kit (Qiagen), quantified by UV spectrophotometry at 260nm, and 20 
\ig were then fragmented by heating at 94°C with CodeLink fragmentation buffer 
for 20 minutes in the presence of magnesium. The fragmented cRNA was 
hybridized overnight at 37°C in hybridization buffer to a UniSet Rat I Bioarray 
(Amersham, Piscataway, NJ, USA) in a shaking incubator at 300 rpm. 
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3.2.3 Post-hybridization processing and Scanning 
After hybridization, slides were taken from the incubator and their hybridization 
chambers were removed. The slides were incubated in 0.75 x TNT (0.1 M 
Tris-HCl, pH 7.6，0.15 M NaCl, 0.05% Tween 20) for 1 h at 46。C. Slides were 
incubated with Streptavidin Alexa Fluor 647 (Molecular Probes, Eugene, OR, 
USA) for 30 min in dark [0.2% Alexa-647 in TNB = 0.1 M Tris-HCl, 0.15 M 
NaCl, 0.5% NEN Blocking Reagent (Perkin Elmer, Wellesley, MA , USA), pH 
7.6]. The slides were washed with Ix TNT four times for 5 minutes at RT, 
followed by washing with O.IX SSC，0.05% Tween 20 for 30s at RT. Slides were 
then dried by low speed centrifugation and kept in dark until scanning. Images 
were captured on an Axon GenePix Scanner (Arlington, TX, USA) using 
CodeLink Expression Scanning Software and were analyzed using CodeLink 
Expression Analysis Software. Laser scanning parameters were 635 nm, PMT 
voltage at 600, power = 100 and the scan area adjusted for the entire array. 
3.2.4 Microarray data analysis 
The array image was analyzed by using Codelink Expression Analysis software. 
This software generated the raw outputs for each spot by the spot intensity versus 
the surrounding background. The raw intensity values were normalized by the 
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control spots. Only the gene spots classified as good or near background were 
used for further analysis. 
The average intensity of each gene was obtained by taking average of the 
normalized intensities from the same rat treatment group. The average intensity of 
each gene among different treatment group was sorted and only two expression 
trends，expression of T〉CT>N>CN and CN>N>CT>T with average fold changes 
between N and T larger than 1.5 were kept for further analysis. 
3.2.5 Quantitative RT-PCR 
Total RNA was extracted by RNA Tri Reagents (CINNA/MRC; Cincinnati, OH, 
USA). After isolation, RNA was assessed by using agarose denature gel. cDNA 
was synthesized from 2 ug of total RNA with oligo (dT)i8 primer and MMLV 
reverse transcriptase (Promega, Madison, WI, USA). Quantitative RT-PCR 
analysis was done by using LightCycler 1.5(Roche, IN, USA) with LightCycler 
FastStart DNA Master''^^^ Hybridization Probes (Roche, IN, USA). The 
sequences of the primers are listed in Table 2. Expression levels were normalized 
to rat /3 -actin. A l l experiments were performed in triplicate. The gene expression 
fold changes between control and celecoxib treated samples were compared by 
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Mann-Whitney U test. A l l statistical analyses were performed with SPSS software 
(version 11.0，SPSS Inc) and a value of ;?<0.05 was considered to be statistically 
significant. 
^ e 1 Lis t of r a t ^ ^ n s . ^ for a u a n m ; t i v e R ^ - P ^ l ^ ^ A � “ ： . . 、 . ， 
Gene Forward primer (5' — 3') Reverse primer (5' —• 3') 
BCL2-antagonist/killer 1 (Bakl� T G T C T G A A C A C G T C C A T C TAACAGGAGCATGGGT 
Acidic calponin (Cnn3) CCTGTCATTCACAACGG CGCGAGTTACTGGTTAG 
Janus protein tyrosine kinase 1 jJakl) AAAGTCCTAGACCCTAGC TGATGAACGGGCCAAT 
Leucine zipper protein 1 (Luzpl) AGTCACCGATGGTTGT ATTACGGGTTGGGGAT 
Aquaporin 7 {Aqp7) ACTTCAAGGGACCGAG TCGTTGGACGATGCTG 
Solute carrier family 6 member 4 (Sk6a4� GGATTCCGACCACTTCT GCGGGGTAGTATGATCTT 
Topoisomerase IIB {Tob2b) AAGTTGCCCAGTTAGC CCGTAACGTGTGATCAT 
Murine thymoma viral oncogene homolog 1 {Aktl) AGAACTCTAGGCATCCC CCGAAGTCCGTTATCTTG 
(3 -ac t in A T C G C T G A C A G G A T G C A G A A G | T C A G G A G G A G C A A T G A T C T T G A 
MKN45 cells were treated with various concentrations of celecoxib (lO-lOOuM) 
for 24 hours. The gene expressions levels were analyzed by quantitative RT-PCR 
using the same protocol as stated previously. The sequences of the primers are 
listed in Table 3. Expression levels were normalized to human 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
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Gene Forward primer (5' — 3') Reverse primer (5' 3') 
Topoisomerase IIB {Tob2b) TTCGTGTAGAGGGGTCA CCACATAATCCACGTGC 
Solute carrier family 6 member 4 {Sk6a4) TGTGTAACACACTCACCG CACACGTCCAAAATAGGC 
Aquaporin 7 {Aqp7) ACGGGATAACCGTATTGC GCCTTGCTTTATTGGGGA 
Liver multidrug resistance-associated protein 6 {Abcc6) ACAATGCTCGCGTAGA AGTTGCGAACAACCCA 
Histamine N-methyltraiisferase {Hnmt) TCTCAACCATTCCACGG GTTCGATGTCTTGGCTAC 
BCL2-antaRonist/killer 1 {Bakl) GACATCAACCGACGCT CGTACCACAAACTGGC 
Acidic calponin {Cnn3) TCAACGAGTCCTCACTG AGTCCCGTAAGCTGTCA 
Janus protein tyrosine kinase 1 jJakl) CCCACAAACACATCGT ACCGTAATGGGGATGC 
Leucine zipper protein 1 (Luzpl) CCACTAGCAATATCCAGG CCGCACAGTAACATGTC 
Glyceraldeliyde-3-phosphate dehydrogenase (GAPDH) I G G A G T C A A C G G A T T T G G T G T G A T G G G A T T T C C A T T G A T 
3.3 Results 
3.3.1 Gene expression profiles of rat gastric tumors 
Three pairs o f M N N G treated gastric tumors (T) and their adjacent non-tumor 
tissues (N), another three pairs of celecoxib treated M N N G induced-gastric 
tumors (CT) and their adjacent non-tumor tissues (CN) were analyzed by the 
normalized intensities generated by the Codelink Expression Analysis software. 
3.3.1.1 Genes differentially expressed in MNNG induced gastric tumors 
Genes that were differentially expressed in MNNG induced gastric tumors (T) and 
its adjacent normal (N) were first determined (group A). When using a cut-off 
value o f more than two-fold in gene expression between tumor and normal tissues, 
75 and 283 genes were found to be up- and down-regulated in the tumors, 
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respectively. By using a stricter criterion of 20-fold changes, 5 and 39 genes were 
up- and down-regulated, respectively (Table 4). 
Genes that were up-regulated in the MNNG-induced rat gastric tumors were 
involved in ion binding, cell adhesion and glutathione transferase activity. 
Examples of genes related to ion binding include Thrombospondin 4 {Thbs4), 
matrix metallopwteinase 2 (Mmp2), Calgranulin-B and metallothionein-III {Mt3). 
Thrombospondin 4 (Thbs4), which can bind calcium ion, is known to act as an 
adaptor protein in extracellular matrix (ECM) assembly [74]. Matrix 
metallopwteinase 2 {Mmp2) is involved in ECM degradation, which is in turn 
related to cancer invasion and metastasis [59]. Calgramilin-B {S100a9), which is 
a skin stress-induced protein, may play a role in carcinogenesis [75]. 
Metallothionein-III {Mt3) plays a major role in the kinetics and metabolism of 
cadmium [76]. Cadmium exposure has been linked to cancer development in renal 
[77], prostate [78] and breast [79]. 
Genes related to cell adhesion were Cell surface glycoprotein CD44 {Cd44), 
Cadherin 17 {Cdhl 7), Glutathione-S-transferase, alpha type {Gstal) and 
microsomal glutathione S-transferase 1 (Mgstl). Cell surface glycoprotein CD44 
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{Cd44) may initiate the metastasis of tumor cells and is important in cell motility, 
proliferation and survival [80]. Cadherin 17 {Cdhl7), also called liver-intestine 
cadherin, is a marker molecule for early detection of gastric intestinal metaplasia 
and well differentiated adenocarcinomas [81]. 
Up-regulating genes related to glutathione transferase activity included 
Glutathione-S-transferase, alpha type (Gsta2) and microsomal glutathione 
S-transferase 1 (Mgstl). Gsta2 can protect cell against cell cycle arrest and 
apoptosis [82]. Mgstl involved oxidative stress response pathway [83] and 
detoxification pathway, which may cause problems during cancer chemotherapy 
[84]. 
Among the down-regulated genes, they were related to DNA binding, 
rhodopsin-like receptor and G-protein couple receptor activity. The p53 gene and 
proliferating cell nuclear antigen {Pcna) are found to be down-regulated in 
MNNG-induced gastric tumors. Example of genes related to rhodopsin-like 
receptor and G-protein couple receptor activity are adenosine Al receptors 
{Adoral) and somatostatin receptor subtype 2 {Sstrl). Adoral is shown to be 
inhibited in human colorectal cancer and may play a role in cell growth and 
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carcinogenesis [85]. Sstr2 has been shown to inhibit the growth of cancer cells 
[86]. 
3.3.1.2 Genes differentially expressed in celecoxib treated group 
By applying the same selection criterion to celecoxib treated group (Group B), 
320 and 619 genes were respectively up- and down-regulated by 2-fold in the 
celecoxib treated rat gastric tumors (CT) as compared to adjacent normal tissues 
(CN). Furthermore, 23 and 113 genes were found to be up- and down-regulated 
by using a stricter criterion of more than 20-fold change. 
The list of genes that are commonly altered in both MNNG and celecoxib groups 
are listed in Table 5. There were two up-regulated and 34 down-regulated genes. 
Troponin T {Tnnt) and Adenosine deaminase {Ada) are the two up-regulated genes 
which is used to monitor cardiotoxicity and participates in production of ammonia, 
respectively [87，88]. One of the down-regulated genes was Pehpherin {Prph2). It 
is an intermediate filament involved in growth and development of the peripheral 
nervous system and has been demonstrated related to neuroblastomas and 
cutaneous neuroendocrine carcinomas[89]. Another down-regulated gene was 
Tumor necrosis factor {Tnf). It is an inflammatory cytokine which can increase the 
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risk of gastric adenocarcinoma[90]. (Table 5). 
3.3.1.3 Mechanisms underlying chemoprevention of celecoxib 
To elucidate the genes responsible for the chemopreventive effects of celecoxib 
on gastric cancer development, we compared the gene expression profiles of the 
two groups (MNNG and celecoxib). Two different expression patterns are 
possible when combining the microarray data of the four groups of gastric tumors 
and adjacent normal tissues. Assuming celecoxib up-regulate genes that are 
downregulated in tumors, the following pattern was identified CN>N〉CT>T 
(Table 6). On the other hand, the T〉CT>N〉CN pattern was obtained when 
celecoxib down-regulate genes that are upregulated in tumors (Table 7). Only 
those genes with average fold changes between N ant T larger than 1.5 were 
shown in the Table 5 and 6. 
In the CN>N>CT>T trend, genes are involved in magnesium ion binding and 
protein kinase activity. One gene from this trend, Neurabin II {Neb2), can interact 
with tumor suppressor ARF to inhibit cell growth[91]. 
In the T>CT>N>CN trend, genes are involved in transporter activity, protein 
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kinase activity and catalytic activity. Glutathione-S-transferase, alpha type (Gstal) 
catalyzes the glutathione reaction and detoxifies activated carcinogens [92, 93]. 
Table 4. Genes with differential expression in MNNG treated rat gastric carcinoma (>20-fold changes) . • ‘ 
Accession Gene Symbol Function Chromosome 
NM一012676.1 Troponin T Tnnt2 Structural constituent 13ql3 
BF404478 Unknown cDNA clone UI-R-CAl-bif-g-lO-O-Ul Obscn Protein binding 10q22 
NM_017081.1 Hydroxysteroid dehydrogenase Hsd 11 b2 Dehydrogenase activity 19q l l -q l2 
NM_012812.1 Cytochrome c oxidase siibunit Via polypeptide 2 Cox6a2 Oxidase activity lq36 
AW 142307 EST 292552 [Ada jpeaminase activity |3q42 
l e a s e d in tumor . “ ， 、 ^ 、 ： > ^ ^ 
AW916655 EST 347959 NULL NULL NULL 
AA8I7877 Unknown cDNA clone UI-R-A0-af-b-03-0-Ul NULL NULL NULL 
NM 031779.1 Amyloid beta (A4) precursor protein-binding, family A Apbal Protein binding k ] ^ 
AA90026丨 Unknown cDNA clone UI-R-E0-de-g-04-0-Ul NULL NULL 3£l3 
AW 143003 EST 293295 NULL NULL NULL 
AA800341 EST 189838 NULL NULL 17ql2.3 
NM 019311.1 Inositol polyphosphate-5-phosphatase lnpp5d Phosphatase activity 
NM 053878.1 Complexin 2 Cplx2 Protein binding 17pl4 
NM 031659.1 Transglutaminase 1，K polypeptide Tgml Transferase activity 15pl3 
NM_Q 12850.1 Growth hormone - releasing receptor Ghrhr G-protein coupled receptor activity 4q24 
BE096021 Unknown cDNA clone Ul-R-BUO-apk-d-lO-O-Ul Jund DNA binding 16pl4 
A1227657 EST 224352 NULL NULL 10q22 
NM 019248.1 Neurotrophic tyrosine kinase’ receptor, type 3 Ntrk3 Kinase activity i ^ S l 
NM 017170.1 Serum amyloid P-component Sap Sugar binding 13q24 
A1070303 Unknown cDNA clone Ul-R-Y0-lt-e-03-0-Ul NULL NULL NULL 
BF281865 EST 446456 NULL NULL NULL 
AI030203 Unknown cDNA clone UI-R-CO-it-li-1 丨-0-Ul NULL NULL 19pll 
NM 013021.1 Peripherin Prph2 Cell adhesion 9ql2 
BE095865 Unknown cDNA clone UI-R-BU0-apb-e-03-0-UI NULL NULL NULL 
NM 012693.1 Cytochrome P45Q IIA2 Cyp2a2 Oxygenase activity j £ 2 1 
All44646 Unknown cDNA clone Ul-R-BTO-pl-d-12-O-UI NULL NULL 10q22 
NM_017140.1 Dopamine receptor 3 Drd3 Rhodopsin-like receptor and G-protein 1 lq21 
Ml3646 Pregnenolone 16-alpha-carbonitrile-indiicible Cyp3a3 NULL 12pl 1 
NM 053404.1 Dynactin siibunit p62 NULL NULL NULL 
NM 022259.1 Non MHC restricted killing associated (Nmrk), mRNA Nmrk Receptor activity 13q24 
NM_012675.1 Tumor necrosis factor, alpha Tnf Cytokine activity 20pl2 
A1237621 EST 234183 NULL NULL lq31 
AW917977 EST 349281 NULL NULL NULL 
NM 012908.1 Tumor necrosis factor superfamily, member 6 Tnfsf6 NULL 13q22 
NM—138535.1 Glutamate receptor interacting protein 2 Grip2 Receptor binding 4q34 
NM 053456.1 Inositol 1.4,5-trisphosphate binding protein Plcll NULL £33] 
NM 031542.1 Breast cancer 2 Brca2 Protein binding 12pl2 
NM_031790.1 I Postsynaptic density protein, citron [Cit [Kinase activity 12ql6 
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NM_012879.1 Solute carrier family 2 A2 Slc2a2 Transporter activity 
NM 031054.1 Matrix metalloproteinase 2 Mmp2 Peptidase activity 19pl 1 
BF412792 Unknown cDNA clone Ul-R-BTl-bnz-d-11-O-UI NULL NULL NULL 
NM 022381.1 Proliferating cell nuclear antigen Pcna DMA binding 3q36 
AJ006070 Recombination activation protein NULL NULL 3q31 
O v e r t — 他 ！ 纖 g 零 争 t 轉 
'： r < Ichro；；；^ 
NM_053626.1 D-ainino acid oxidase |Daol 丨Oxidase activity | l 2 q l 6 
二 o r - 观 ‘ ’、-、 -
NM_012676.1 Troponin T Tnnt2 Structural constituent 13ql3 
AW142307 EST 292552 Ada | Deaminase activity |3q42 
D^^ i^ascd in t u m o r ？ “ • ^ ^ ^ S l ； 編 機 M l ： ^ 〉 — ^ ? ^ � ： ’ ‘ . . . : ; � � . . : . / 丨 
AA800341 EST 189838 NULL NULL 17ql2.3 
NM 031779.1 Amyloid beta (A4) precursor protein-binding, family A Apbal Protein binding I c ^ 
AA817877 Unknown cDNA clone Ul-R-A0-af-b-03-0-Ul NULL NULL NULL 
NM 019311.丨 Inositol polyphosphate-5-phosphatase lnpp5d Phosphatase activity M ^ 
NM 053878.1 Coniplexin 2 Cplx2 Protein binding 17pl4 
BF281865 EST 446456 NULL NULL NULL 
NM 012850.1 Growth hormone releasing receptor Ghrhr G-protein co叩led receptor activity 4q24 
NM 031659.1 Transglutaminase 1 Tgrnl Transferase activity 15pl3 
NM 053626.1 D-amino acid oxidase Daol Oxidase activity 12ql6 
NM 012693.1 Cytochrome P450 IIA2 Cyp2a2 Oxygenase activity 
NM 017170.1 Serum amyloid P-componeiit (Apes), niRNA Sap Sugar binding 13q24 
NM 138535.1 Glutamate receptor interacting protein 2 Grip2 Receptor binding M 4 
AI227657 EST 224352 NULL NULL 10q22 
A 1 2 3 7 6 2 1 E S T 2 3 4 1 8 3 N U L L N U L L M ] 
A1070303 Unknown cDNA clone Ul-R-YO-lt-e-03-Q-Ul NULL NULL NULL 
NM 053404.1 Dynactin siibunit p62 NULL NULL NULL 
NM 017140.1 Dopamine receptor 3 Drd3 Rhodopsin-like receptor and G-protein l lq21 
NM 031054.1 Matrix metalloproteinase 2 Mmp2 Peptidase activity 19pll 
NM 053456.1 Inositol 1,4,5-trisphosphate binding protein Plcll NULL M i 
BE096021 Unknown cDNA clone Ul-R-BUO-apk-d-10-0-UI Juiid DNA binding 16pl4 
AA900261 Unknown cDNA clone Ul-R-EQ-de-R-04-0-UI NULL NULL M i 
M13646 Pregnenolone 16-alpha-carbonitrile-inducible cytochrome Cyp3a3 NULL 12pl 1 
BE095865 Unknown cDNA clone UI-R-BUO-叩b-e-03-0-UI NULL NULL NULL 
BF412792 Unknown cDNA clone UI-R-BTl-bnz-d-11-0-Ul NULL NULL NULL 
NM 012908.1 Tumor necrosis factor superfamily, member 6 Tnfsf6 NULL 13q22 
NM 012879.1 Solute carrier family 2 A2 Slc2a2 Transporter activity 2q24 
A1030203 Unknown cDNA clone UI-R-CO-it-h-11-0-UI NULL NULL 19pll 
NM 013021.1 Peripherin Prph2 Cell adhesion 9ql2 
NM 031542.1 Breast cancer 2 Brca2 Protein binding 12pl2 
NM 022381.1 Proliferating cell nuclear antigen Pcna DNA binding 3q36 
NM 012675.1 Tumor necrosis factor, alpha Tiif Cytokine activity 20pl2 
NM 022259.丨 Non MHC restricted killing associated Ninrk Receptor activity 13q24 
NM 031790.1 Postsynaptic density protein, citron Cit Kinase activity 12ql6 
A W 9 1 7 9 7 7 I E S T 349281 I N U L L | N U L L I N U L L 
- 4 5 -
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NM_017013.1 Glutathione-S-transferase, alpha type Gstal Transferase activity 8q31 
AW143959 EST 294255 NULL NULL NULL 
NM 012786.1 Cytochrome c oxidase subunit VIll-H Cox8h Oxidase activity lq41 
BF284311 EST 448902 NULL NULL 18qll 
AW142307 EST 292552 Deaminase activity 3q42 
NM 013034.1 Solute carrier family 6, member 4 Slc6a4 Symporter activity 10q26 
BE099999 Unknown cDNA clone UI-R-BJl-atr-e-lO-O-Ul NULL NULL 
BF386111 Unknown cDNA clone Ul-R-CAl-bba-b-05-0-UI NULL NULL ^ 
AA818120 Unknown cDNA clone Ul-R-AO-am-g-11 -0-UI NULL NULL 
AW916805 EST 348213 NULL NULL NULL 
NM_019I57.1 Aquaporin 7 Aqp7 Transporter activity 5q22 
NM 013012.1 cGMP dependent protein kinase type II Prkg2 Kinase activity 14p22 
NM_017336.1 Receptor-type protein tyrosine phosphatase D30 Ptpro Phosphatase activity 4q44 
NM 031044.1 Histamine N-methyltransferase Hnmt Methyltransferase activity 3pl3 
NM 031746.1 Solute carrier family 13，member 2 Slcl3a2 Transporter activity 10q25 
Al 105049 EST 214338 NULL NULL NULL 
NM 031971.1 Heat shock protein 70-1 Hspala Cliaperone activity 20pl2 
NM 012530.1 Creatine kinase, muscle form Ckm Kinase activity 
NM—133424.1 Actinin alpha 3 Actn3 NULL 
A1228222 EST 224917 NULL NULL NULL 
AB009372 Lysophospholipase LOC246266 NULL 6£32 
NM 031533.1 AndrosteroneUDP-Rluciironosyltransferase Udpgt Gliicuronosyltransferase 14p21 
U27518 UDP-glucuronosyltransferase LOC286989 NULL 14p21 
NM 017341.1 Lingual lipase NULL k j ^ 
NM 133621.1 Global ischemia induced protein GllglSb NULL H p l l 
NM 053785.1 Transmembrane 4 superfamily member 4 Tm4sf4 NULL 2q31 
AW141867 EST 291982 NULL NULL Xq37 
NM—021850.1 Bcl-w protein Bcl212 Apoptosis inhibitor 15pl3 
AW919146 EST 350450 NULL NULL 10q24 
BF284889 EST 449480 NULL NULL 17ql2.1 
AFl 89709 Collagen XVIll Coll Sal NULL 20pl2 
AI231802 EST 228490 Plm NULL 20ql l 
NM 017139.1 Preproenkephalin’ related sequence Peiik-rs NULL 5c[12 
BE098212 Unknown cDNA clone Ul-R-BJl-asz-b-05-0-UI NULL NULL 
NM 013061.1 Sucrase-isomaltase ^ Catalytic activity 2332 
NM 130401.1 Membrane-associated protein 17 M叩 17 NULL 5q36 
X83579 Cdk-activating kinase Cdk7 Kinase activity 
NM 053372.1 Leukocyte protease inhibitor ^ NULL 3£42 
A1045288 Unknown cDNA clone UI-R-Cl-ju-e-Ol-O-Ul NULL NULL 20ql3 
AW915454 EST 346758 NULL NULL NULL 
A1234014 EST 230702 NULL NULL NULL 
A1578745 Unknown cDNA clone Ul-R-AAO-wq-f-l 丨-0-UI NULL NULL NULL 
AA8 丨 8643 Unknown cDNA clone UI-R-A0-az-l-Q4-Q-Ul NULL NULL NULL 
NM 053810.1 ISynaptosomal-associated protein, 29kD |snap29 INULL | l l q 2 3 
- 4 6 -
BF412073 Unknown cDNA clone UI-R-BTl-bmy-c-08-0-UI LOC304109 NULL l l q l l 
U69550 Phospholipase D P l ^ Catalytic activity 2q23.3-q24 
AW 141928 EST 292043 Vnnl N U L L l ^ n 
NM_053385.1 Proline arginine-rich end leucine-rich repeat protein Prelp NULL 13ql3 
ABO 11533 M E G F 7 j ^ g i NULL Sggf 
AI171617 EST 217586 NULL NULL 17pl2 
A1231808 EST 228496 NULL NULL 2g41 
AW914881 EST 346185 NULL NULL NULL 
AW528898 Unknown cDNA clone Ul-R-BTl-ak.i-h-03-0-UI NULL NULL NULL 
N M 019273.1 Potassium large conductance calcium-activated channel Kcnmbl N U L L 10ql2 
BF563403 Unknown cDNA clone UI-R-BTl-akh-c-Ol-O-UI NULL NULL T^IJ 
AF139830 Insulin-like growth factor binding protein 5 IgfbpS Growth factor binding 9q33 
A l l 7 7 3 7 9 EST 220999 NULL NULL NULL 
N M 138519.1 D i c k k o p f h o m o l o g 3 Dkk3 NULL M 3 
A l l 0 2 2 3 6 EST 211525 NULL NULL NULL 
VO 1224.1 Alpha-actin Actal Motor activity 19ql2 
N M 133600.1 Solute carrier family 31 member 1 Slc31al NULL 
BF5657Q5 Unknown cDNA clone UI-R-BO1 -ajp-b-07-0-UI NULL N U L L NULL 
AW918022 EST 349326 NULL NULL M ] 
BF420018 Unknown c D N A clone UI-R-BJ2-bpm-a-08-0-UI NULL NULL NULL 
AI409635 EST 237927 NULL NULL NULL 
AA859796 Unknown c D N A clone UI-R-EO-bu-g-lO-O-Ul L0C312670 NULL 4£42 
N M 012922.1 C a s p a s e 3 Casp3 Peptidase activity 16q l l 
AW914966 EST 346270 NULL NULL NULL 
BF412111 Unknown cDNA clone UI-R-BTl-bmv-g-07-0-UI NULL NULL NULL 
BF387347 Unknown cDNA clone Ul-R-CAl-bbr-d-06-0-UI NULL NULL NULL 
BE 110731 Unknown cDNA clone Ul-R-BJl-avd-g-08-0-UI NULL NULL 10q22 
N M 012827.1 Bone morphogenetic protein 4 Bmp4 Cytokine activity 15pl4 
NM_017173 .1 Serine proteinase inhibitor, member 1 Serpinlil Chaperone activity lq32 
A W 144302 EST 294598 NULL NULL NULL 
N M 130829.1 Paralemmin Palm NULL 
AI070137 Unknown cDNA clone UI-R-Y0-lu-f-09-0-Ul Aoc3 Cell adhesion 10q32.1 
BF551173 Unknown cDNA clone Ul-R-Cl-Jv-a-l 1-0-UI NULL NULL 
BE 113048 Unknown c D N A clone UI-R-BJl-awf-R-06-0-UI Rtn2 NULL 1 £ 2 ] 
N M 053445.1 Fatty acid desaturase 1 Fadsl NULL M ^ 
AW520812 Unknown cDNA clone UI-R-BJ0p-agh-g-08-0-UI NULL NULL NULL 
NM_031013 .1 Liver mult idrug resistance-associated protein 6 Abcc6 Nucleotide binding lq22 
BE 117002 Unknown c D N A clone UI-R-BS1 -ayl-f-12-0-UI LOCI70927 NULL 
J05499 L-glutamine amidohydrolase ^ Glutaminase activity 7 q l l 
N M _ 031640.1 Plasma glutamate carboxypeptidase Pgcp NULL 7q22 
D14046 DNA topoisomerase IIB Top2b DNA topoisomerase NULL 
N M 019229.1 Solute carrier family 12, member 4 S lc l2a4 Transporter activity 19ql2 
AI171219 E S T 2 1 7 1 7 3 Hdgfrp2 NULL NULL 
N M 013086.1 C A M P responsive element modulator Crem NULL 17ql2.1 
AW917600 EST 348904 NULL NULL NULL 
N M 012591.1 Interferon regulatory factor 1 Irf l DNA binding 10q22 
N M 021758.1 Lin-7-A Vel i la NULL Ic[22 
BF551318 Unknown cDNA clone Ul-R-CO-il-f-11-0-Ul N U L L N U L L 2 0 p l l 
N M 080786.1 |Solute carrier family 21 Isic21a9 INULL | l q 3 2 
- 4 7 -
BE109102 Unknown cDNA clone UI-R-BSl-azb-a-05-0-UI NULL NULL NULL 
A l l 7 0 6 7 1 EST 216607 NULL NULL NULL 
N M 012621.1 6-Phosphofructo-2-kinase/tructose-2,6-bisphosphatase 1 P fk fb l Catalytic activity Xq22-q31 
AW917256 EST 348560 NULL NULL ^ 
A1556488 Unknown cDNA clone UI-R-C2p-rk-d-l 1-0-Ul NULL NULL 10q32.3 
AF130881 Ryanodine receptor type 3 Rj^rS Receptor activity SgM 
BF557396 Unknown cDNA clone UI-R-C0-gr-e-03-0-UI NULL NULL 
AW915241 EST 346545 NULL NULL M p l l 
AW916860 EST 348073 NULL NULL NULL 
NM_012755.1 Fyn proto-oncogene Fyn Kinase activity 2 0 q l 3 
NM_024375.1 Prepro bone inducing protein GdflO Cytokine activity 16pl6 
BF522885 Unknown c D N A c l o n e UI-R-YO-aco-e-11-0-Ul NULL NULL l l q l 2 
N M 032084.1 Chimerin 2 Chn2 Receptor activity 
N M 053603.1 Chloride intracellular channel 5 Clic5 Ion channel 
BF285565 EST 450066 NULL NULL NULL 
N M 031066.1 Protein kinase C-binding protein Zetal F e ^ NULL M l 
AA892496 EST 196299 Chn2 Receptor activity 4q24 
AA8 丨 7802 Unknown cDNA clone UI-R-A0-ae-b-09-0-UI NULL NULL NULL 
N M 012949.1 Muscle specific enolase (beta beta enolose) &no3 Magnesium ion binding 10q24 
X99723 Homologue o f b r a h m a protein Smarca4 NULL M i 
N M 021863.1 Testis-specific heat shock protein-related gene hst70 Hspt70 NULL 
N M 030829.1 G protein-coupled receptor kinase 5 GprkS Kinase activity M 5 
BE 106542 Unknown cDNA clone Ul-R-BOl-asp-b-12-O-Ul NULL NULL 13q24 
N M 017024.丨 Lecithin-cholesterol acyltransferase Lcat Catalytic activity 19ql2 
BF398712 Unknown cDNA clone Ul-R-BS2-bes-d-l 1-0-UI NULL NULL M i 
NM_053535 .1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 Enppl Nucleic acid binding l p l 2 
AF3 丨4%0 Hic-5/ARA55 protein T g f b l i l Protein binding M 6 
N M 012905.1 Aortic preferentially expressed gene 1 Apegl Kinase activity M ^ 
N M 013097.1 Deoxyribonucleasc I Dnasel N U L L 卿 2 
AF106657 Deubiquitinating enzyme U b p l 0 9 U s p l 5 Protease activity 7g22 
M30596 Cytosolic malic enzyme Me l Enzyme activity ^ 
AW143256 EST 293552 NULL NULL NULL 
AW530292 Unknown cDNA clone Ul-R-BU0-amu-h-09-0-UI NULL MULL NULL 
AJ245707 2-hydroxyphytanoyl-CoA lyase Hpcl2 NULL 16pl6 
N M 017312.1 Bcl-2-related ovarian killer protein Bok Apoptosis activator M 6 
A1233818 EST 230506 A k a p l 2 NULL M i 
BE 108968 Unknown cDNA clone Ul-R-BSl-aza-e-03-0-UI NULL NULL NULL 
N M 053511.1 Neural F box protein NFB42 Fbxo2 NULL i £ 3 6 
AW 142440 EST 292692 NULL NULL NULL 
X96392 Outer membrane cytochrome b5 omb5 Electron transporter 19ql2 
A1406984 EST 235272 ItgaS NULL 17ql2.3 
AW252152 Unknown cDNA clone Ul-R-BJO-aee-g-12-O-Ul GCX-1 NULL M ? 
U13253 Lipid-binding protein NULL NULL IMl：^ 
N M 024386.1 3-hydroxy-3-methylglutaryl CoA lyase Hmgcl Catalytic activity 
BF284840 EST 449431 NULL NULL N U L L 
N M 017049.1 Solute carrier family 4, member 3, anion exchange protein 3 Slc4a3 Ion exchanger M i 
AF335571 Microtubule-associated protein EMAP Eml2 Receptor binding 1921 
X13016 M R C OX-45 surface antigen Cd48 NULL 1 M 4 
BF543356 |Unknown c D N A clone UI-R-YO-abfi-f-l 1-0-UI [Hrc | n U L L I M ? 
- 4 8 -
BE 109120 Unknown cDNA clone UI-R-BS1 -azb-b-11 -0-UI NULL NULL 15q24 
BEl 16582 Unknown cDNA clone Ul-R-BSl-ayj-h-08-0-Ul Rock2 Kinase activity 6q l5-q l6 
AW527424 Unknown cDNA clone UI-R-BO1 -ajt-b-12-Q-UI NULL NULL ^ 
BF550302 Unknown cDNA clone UI-R-Al-ef-c-03-0-UI NULL NULL NULL 
AA849738 EST 192505 NULL NULL NULL 
NM 053516.1 Unknown Glu-Pro dipeptide NULL NULL NULL 
NM_054002.1 Leukemia/lymphoma related factor U f Repressor activity 7ql 1 
AW920324 EST 351628 NULL NULL NULL 
NM 053758.1 Phospholipase C Plcel NULL 
NM, 019341.1 Regulator of G-protein signaling 5 Rgs5 Signal transducer 13q24 
AW143101 EST 293397 NULL NULL NULL 
BF405725 Unknown cDNA clone Ul-R-CAl-bJe-c-13-O-UI LOC266762 NULL _l£42 
BF562759 Unknown cDNA clone Ul-R-BJOp-aij-h-lO-O-UI NULL NULL NULL 
BF387327 Unknown cDNA clone Ul-R-CAl-bbr-b-09-0-Ul NULL NULL NULL 
BF2 82462 EST 447053 NULL NULL NULL 
AA848305 EST 191065 Rap lb NULL 
BF399328 Unknown cDNA clone UI-R-CAl-bib-c-22-O-Ul Mucks Kinase activity NULL 
AW916911 EST 348124 NULL NULL NULL 
BEl 13264 Unknown cDNA clone UI-R-BJl-avvd-d-09-0-UI NULL NULL M ^ 
BF281787 EST 446378 NULL NULL NULL 
AW916819 EST 348227 NULL NULL 
AI317813 EST 234484 NULL NULL NULL 
AW 143980 EST 294276 NULL NULL NULL 
All 76825 EST 220424 NULL NULL NULL 
NM 021262.1 Acid phosphatase 1 S o ^ NULL 
AI411352 EST 239646 GJal Channel _18 
L02530 Drosophila polarity gene (frizzled) F ^ Receptor activity NULL 
BF409296 Unknown cDNA clone UI-R-CAl-ble-d-03-0-UI NULL NULL 
BF400832 Unknown cDNA clone UI-R-CA0-bhf-R-03-0-Ul NULL NULL NULL 
AF311728 Angiopoietin-2 Agpt2 NULL 16ql2.5 
D13341 MAP kinase kinase Map2kl Kinase activity 8q24 
BF567904 Unknown cDNA clone UI-R-BOO-aho-h-02-Q-Ul NULL NULL 
NM. 012980.1 Matrix metalloproteinase 11 M m p l l Peptidase activity 20pl2 
NM 033230.1 Murine thymoma viral (v-akt) oncogene homolog 1 Kinase activity 6q32 
NM 134370.丨 Exchange factor for ARF6 EFA6 NULL 
NM 012834.1 Cartilage oligomeric matrix protein Comp Cell adhesion NULL 
AI011711 EST 206162 NULL NULL NULL 
AI411962 EST 240256 NULL NULL 18qll 
NM_080886.1 Sterol-C4-methvl oxidase-like Sc4mol Catalytic activity 16pl3 
A1409877 EST 238170 NULL NULL M ] 
NM 017066.1 Pleiotrophin Ptn Growth factor A ^ 
BE097553 Unknown cDNA clone UI-R-BOl-apy-h-12-O-UI NULL NULL NULL 
NM 031573.1 Phosphorylase kinase, gamma 1 Phkgl Kinase activity 12ql3 
NM 053735.丨 Phosphatidylinositol 4-kinase type II Pi4KII Kinase activity i s M 
NM 019368.1 Blocked early in transport 1 homolog like Bet 11 Bet 11 NULL l£41 
AW527690 Unknown cDNA clone Ul-R-BTl-aiv-b-02-0-UI NULL NULL NULL 
A1013913 EST 208588 Caldl Actin binding 
NM_019379.1 Vesicle docking protein Vdp Transporter activity 14p22 
AA850490 |EST 193257 INULL |NULL INULL 
- 4 9 -
- 50-
N M 054003.1 Beta-l,3-glucuronyltransferase 1 B3gatl Tansferaseactivity 8 q l 3 
NM 053962.1 Serine dehydratase ^ NULL NULL 
J00744 Ig epsilon heavy chain NULL NULL ^ 
AW918419 EST 349723 NULL NULL 10q32.3 
NM 013070.1 Utrophin Utm NULL ^J&ii 
NM 031098.1 Rho-associated kinase beta Rockl NULL 18pl3 
N M 017073.1 Glutamine synthetase Gins Ligase activity 13q22 
NM 017224.1 Solute carrier family 22. member 6 Slc22a6 Transporter activity lq43 
BF284374 EST 448965 NULL NULL NULL 
AA874859 Unknown cDNA clone UI-R-E0-ci-a-08-0-UI NULL NULL NULL 
N M 031012.1 Alanyl aminopeptidase Anpep Peptidase activity lq31 
N M 134404.1 SV2 related protein Syo^ NULL 12ql6 
N M 017167.1 Opioid receptor, kappa 1 Oprkl G-protein receptor 5 q l l 
N M 017113.1 Granulin ^ Phospholipase activity 10q32.1 
N M 032070.1 Non-histone chromosomal architectural protein HMGI-C Hmgic NULL T g ^ 
BF396279 Unknown cDNA clone UI-R-BS2-bdw-c-l 1-0-Ul NULL NULL 17ql2.3 
NM 053598.1 Diphosphoinositol polyphosphate phosphohydolase type II Nudt4 Phosphatase activity 7 q l 3 
B1281891 Unknown cDNA clone UI-R-CUQs-cbt-g-OS-O-UI NULL NULL 
NM 133537.1 Extracellular proteinase inhibitor ^ NULL 10q26 
BE 119676 Unknown cDNA clone UI-R-CA0-baz-f-06-0-UI NULL NULL NULL 
Al 137751 Unknown cDNA clone UI-R-El-fi{-f-05-0-UI NULL NULL NULL 
AA946181 EST 201680 NULL NULL M 3 
U75924 Retinoblastoma susceptibility gene mRNA NULL NULL NULL 
AI103349 EST 212638 NULL NULL 3343 
BE097587 Unknown cDNA clone Ul-R-B01-apz-d-02-0-Ul NULL NULL l l q 2 2 
AI408580 EST 236870 NULL NULL 
N M 134465.1 Thymic stromal-derived lympliopoietin, receptor Tslpr Cytokine activity NULL 
N M 053992.1 Neuroligin 2 NlRn2 Catalytic activity 10q24 
AW919304 EST 350608 NULL NULL NULL 
AFl 10025.丨 RST transporter homolog Slc22al2 NULL M ] 
BE 108224 Unknown cDNA clone UI-R-BSl-ayw-h-Ol-O-UI NULL NULL NULL 
N M 053611.1 Nuclear proten 1 Nuprl Transcription factor lq36 
A1230228 EST 226923 PsaU NULL 1^43 
BF396424 Unknown cDNA clone Ul-R-BS2-bdy-a-03-0-UI NULL NULL NULL 
AI411580 EST 239874 NULL NULL l l q 2 3 
BE 102111 Unknown cDNA clone Ul-R-BTl-aqi-e-04-Q-UI NULL NULL M i 
Al l 78361 EST 222030 NULL NULL 12q l l 
BE109164 Unknown cDNA clone Ul-R-BSl-azb-f-08-0-UI NULL NULL NULL 
BE 112551 Unknown cDNA clone Ul-R-BJ 1 -avn-a-05-0-UI NULL NULL 17pl4 
AW918169 EST 349473 NULL NULL NULL 
BE108368 Unknown cDNA clone UI-R-BSl-ayv-e-Ol-O-UI NULL NULL NULL 
N M 021854.1 Tuberous sclerosis 1 T s ^ Protein binding M ^ 
N M 012774.1 Glypican 3 G£c3 NULL Xq36 
BF557672 Unknown cDNA clone UI-R-C0-ib-a-09-0-Ul NULL NULL NULL 
NM 013174.1 Transforming growth factor, beta 3 T g f t 3 Growth factor receptor 6q31 
AW915444 EST 346748 NULL NULL 4£34 
Al 136350 Unknown cDNA clone Ul-R-C2p-od-a-07-0-UI Slc3al Amylase activity §£12 
Al 172618 Unknown cDNA clone UI-R-C2p-oh-h-03-Q-Ul NULL NULL NULL 
AW533508 |Unknown cDNA clone UI-R-BUO-ani-G-Ol-O-Ul INULL INULL |6q32 
- 5 1 -
N M 080481.1 A T P synthase, subunit e Atp5k NULL 14p22 
A m 2 0 5 4 EST 240348 NULL NULL NULL 
AI228258 EST 224953 NULL NULL NULL 
N M 021264.1 Ribosomal protein L35a NULL NULL NULL 
N M 031587.1 Peroxisomal membrane protein 2 Pxmp2 NULL 12ql6 
AI717736 Unknown cDNA clone UI-R-Y0-acq-h-Q9-0-UI NULL NULL NULL 
N M 017251.1 Gap junction membrane channel protein beta 1 Gjb l Channel forming Xq31 
AA893184 EST 196987 NULL NULL M l 
NM_031782 .1 Vesicular inhibitory amino acid transporter Viaat Transporter activity 3q42 
AW435041 Unknown cDNA clone UI-R-BJ0p-afv-h-09-0-Ul NULL NULL 10q32.3 
AI044229 Unknown cDNA clone UI-R-Cl-kb-d-lO-O-UI NULL NULL 
N M 012953.1 Fos-like antigen 1 Fosll DNA binding k[43 
N M 032614.1 Thioredoxin-l ike 2 Txnl2 Protein kinase C binding lq41 
N M 133622.1 Salivary protein 1 LOC171161 NULL NULL 
A l l 02771 EST 212060 NULL NULL NULL 
N M 019177.1 Selectin ^ Cell adhesion 13q22 
U15408 Plasma membrane Ca2+-ATPase isoform 4 Atp2b4 Magnesium ion binding 13ql3 
A1599411 EST 251114 NULL NULL NULL 
AFl 86469 T M 6 P 1 Tm6pl NULL 1333 
A W 1 4 4 5 0 2 E S T 2 9 4 8 7 9 N U L L N U L L N U L L 
AI231190 EST 227878 NULL NULL BgSS 
BE099881 Unknown cDNA clone Ul-R-BJl-atl-c-05-0-UI NULL NULL NULL 
N M 013223.1 Hemin-sensit ive initiation fac tor2a kinase E iOak l Kinase activity 12p l l 
BE 109711 Unknown c D N A clone Ul-R-BJ 1 -aup-c-06-0-UI NULL NULL \5q\l 
BE098827 Unknown cDNA clone UI-R-BJl-ate-c-1 丨-0-UI NULL NULL NULL 
N M 053685.1 Hyperpolarization-activated, cyclic nucleotide-gated Hcn3 NULL 2q34 
N M 017012.1 Glutamate receptor, metabotropic 5 Grm5 G-protein coupled lq32 
AF021923 Potassium-dependent sodium-calcium exchanger NULL NULL NULL 
BF548454 Unknown c D N A clone UI-R-AQ-aa-e-03-0-Ul NULL NULL NULL 
AA799614 EST 189111 Sirt2 N U L L M l 
AA892522 EST 196325 NULL NULL NULL 
BE100318 Unknown c D N A clone UI-R-BJl-att-b-06-0-UI NULL NULL NULL 
A1169058 EST 214887 NULL NULL 
BF401587 Unknown cDNA clone Ul-R-CA0-bgm-d-04-0-UI NULL NULL M ? 
N M 021693.1 Salt-inducible protein kinase Snf l lk Kinase activity 2 0 p l 2 
AW531250 Unknown c D N A clone UI-R-BSO-aml-d-12-O-UI NULL NULL NULL 
AI575225 Unknown c D N A clone UI-R-Y0-vc-a-04-0-Ul NULL NULL 14q21 
U20796 Nuclear receptor Rev-ErbA-beta N r l d 2 DNA binding 15pl6 
AF007890 Resection-induced TPI NULL NULL NULL 
N M 019155.1 Caveolin 3 Cav3 NULL 1342 
N M 020088.1 Neurest in alpha Odz2 NULL 卿 2 
L I 9 9 2 7 A T P synthase gamma-subunit Atp5cl NULL 17ql2.3 
BF556841 Unknown cDNA clone UI-R-El-fo-c-08-0-UI NULL NULL NULL 
BE107234 Unknown cDNA clone UI-R-BSl-ayr-d- l 1-0-UI NULL NULL \ \ ( \ l \ 
BE329232 c D N A clone 3121673 NULL NULL 
BE 118440 Unknown cDNA clone UI-R-BJl-azp-f-05-0-UI NULL NULL NULL 
BE 112768 Unknown c D N A clone UI-R-BJ1 -avo-e-12-0-UI NULL NULL NULL 
AIO10251 EST 204702 Rnase4 Nucleic acid binding 15pl4 
AW919982 I EST 351286 INULL INULL [NULL 
- 5 2 -
N M 030830.1 Leucine zipper protein 1 Luzpl NULL 4 
A1177867 EST 221516 NULL NULL l £ 4 3 
BF282646 EST 447237 NULL NULL 2 0 q l l 
AA800210 EST 189707 Csnk2al Kinase activity 3£41 
N M 012634.1 Phophoribosylpyrophosphate synthetase, subunit II Prps2 Magnesium ion binding Xq21 
A1598410 EST 250113 NULL NULL 17q l l 
BE 115519 Unknown cDNA clone UI-R-BS 1 -axw-g-10-0-UI NULL NULL 17pl2 
N M 053331.1 Thioredoxin T ^ Electron transporter 7q34 
M60616 Collagenase M m p l 3 Peptidase activity 8 q l l 
AW918276 EST 349580 NULL NULL NULL 
AW534 丨 66 Unknown cDNA clone Ul-R-C4-alq-a-02-0-UI NULL NULL M J 
AW916745 EST 348153 NULL 17pl4 
AA875041 Unknown cDNA clone UI-R-EQ-cb-b-03-0-UI Psdzip70 NULL 16pl4 
N M 053771.1 Lens intrinsic membrane protein 2 Lim2 Structural constituent lq22 
A I 4 0 6 9 4 1 E S T 2 3 5 2 2 9 N U L L N U L L N U L L 
N M 017228.1 Dentatorubral pallidoluysian atrophy Drpla Toxin activity 4£42 
N M 019359.1 Acidic calponin Cnn3 Actin binding M i 
BF398756 Unknown cDNA clone UI-R-BS2-bes-b-02-0-UI NULL NULL NULL 
N M 017364.1 Pancreas zinc finger protein Z n f l 4 6 NULL M j 
BF406213 Unknown cDNA clone Ul-R-CAl-bif-e-12-O-Ul Ndufa5 Dehydrogenase activity 4q22 
AF150091 Small zinc finger-like protein TimmlO N U L L 
AA945099 EST 200598 NULL NULL NULL 
N M 031629.1 Proteasome subunit, beta type, 4 Psmb4 Peptidase activity 2q34 
BE 104346 Unknown cDNA clone Ul-R-BX0-arn-g-03-0-Ul NULL NULL M i 
BF284994 EST 449585 NULL NULL H q l l 
BF282796 EST 447387 NULL NULL 15q25 
N M 017274.1 Glycerol-3-phosphate acyltransferase, mitochondrial Gpam Acyltransferase activity lq55 
BF286131 EST 450722 NULL NULL 
U69702 Activin-like receptor kinase-7 Alk7 NULL 3£21 
AA892818 EST 196621 NULL NULL NULL 
N M 053371.1 Fracture callus 1 NULL M 3 
BF558780 Unknown c D N A clone UI-R-Al-dt-d-02-0-UI NULL NULL 卿 1 
N M 031719.1 Chloride channel, nucleotide-sensitive, 1A Clns la NULL M Z 
N M 031834.1 Sulfotraiisferase family lA, phenol-preferring, member 1 Su l t l a l Transferase activity NULL 
J05266 Mitochondrial H+-ATP synthase alpha subunit Atp5al ATP-binding 
N M 017193.1 Kynurenine aminotransferase II Kat2 Transaminase activity 16pl2 
N M 032057.1 丨nositol (myo) - l (o r 4)-monophosphatase 1 Impal Magnesium ion binding 2q23 
BF408867 Unknown cDNA clone Ul-R-BS2-bet-c-l 1-0-Ul NULL NULL M i 
B E l 10658 Unknown cDNA clone UI-R-BJl-avu-e-06-0-Ul NULL NULL NULL 
AI410700 EST 238993 NULL N U L L 
BE 106832 Unknown c D N A clone UI-R-BTl-ast-f-lO-O-Ul NULL NULL 6£32 
N M 012707.1 Glucagon G ^ Hormone 3q22-q24 
AW254246 Unknown cDNA clone UI-R-BJ0-aev-d-04-0-UI NULL NULL NULL 
AI411270 EST 239564 NULL NULL NULL 
AI234810 EST 231372 NULL NULL NULL 
BF283407 EST 447998 NULL N U L L NULL 
N M 030836.1 Leucyl-specific aminopeptidase PILS Appils NULL M i 
BE099459 Unknown c D N A clone UI-R-BJl-atw-c-04-0-UI NULL N U L L 10^32.3 
A 1 1 0 1 4 5 8 I E S T 2 1 0 7 4 7 I N U L L [ N U L L I N U L L 
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BF414043 Unknown cDNA clone UI-R-BJ2-bol-g-02-0-Ul NULL NULL 3£35 
N M 053832.1 Forkhead box J1 Serpinal NULL 6£32 
AW915369 EST 346673 NULL NULL 12ql2 
BF553139 Unknown c D N A c l o n e UI-R-C2-ni-c-02-0-UI NULL NULL 19q l l 
NM—017040.1 Protein phosphatase 2’ catalytic subunit, beta isoform NULL NULL NULL 
AW917212 EST 348516 NULL NULL 6 £ l 2 
BF282700 EST 447291 NULL NULL 
AA850910 EST 193678 NULL NULL Xq34 
BE 109603 Unknown cDNA clone Ul-R-BJl-avq-a-09-0-UI NULL NULL 
N M 012675.1 Tumor necrosis factor, alpha Tnf Cytokine activity 2 0 p l 2 
BE 108670 Unknown cDNA clone UI-R-CA0-axh-a-06-0-Ul NULL NULL NULL 
BE109919 Unknown cDNA clone UI-R-CA0-axi-h-06-0-UI NULL NULL NULL 
N M 053812.1 BCL2-antagonist /kiner 1 B a k j Apoptosis activator 2 0 p l 2 
A1236816 EST 233378 NULL NULL T^M 
AI233718 EST 230406 NULL NULL NULL 
BF282876 EST 447467 NULL NULL NULL 
N M 017246.1 Mitogen activated protein kinase kinase 5 Map2k5 Kinase activity 
AA819871 Unknown cDNA clone UI-R-A0-aq-a-07-0-Ul NULL NULL 16ql2.5 
AW534 丨 51 Unknown cDNA clone UI-R-C4-alp-R-09-0-UI NULL NULL _ 6 
BF416249 Unknown cDNA clone UI-R-CA0-bkr-c-04-0-UI NULL NULL NULL 
AB073318 Dem-A20-4 Baalc NULL M i 
AW251204 Unknown cDNA clone UI-R-BJ0-adf-d-06-0-Ul NULL NULL NULL 
A1072958 Unknown cDNA clone Ul-R-YO-ly-b-12-O-Ul NULL NULL NULL 
N M 133599.1 Lectin, galactoside-binding, soluble 2 Lgals2 Galactoside binding 7q34 
AA892549 EST 196352 NULL NULL NULL 
N M 017220.1 6-pyriivoyl-tetrahydropterin synthase Pts Magnesium ion binding 8q23 
AJ000556 .lanus protein tyrosine kinase 1 JaM Kinase activity 5q31.3-q35 
AF 136584 Protein kinase FNK Cnk Kinase activity 
AW253947 Unknown cDNA clone UI-R-BJ0-aed-c-03-0-UI NULL NULL NULL 
BF404556 Unknown cDNA clone Ul-R-CAl-big-d-07-0-Ul NULL NULL 10q32.3 
AF030050 Replication factor C Reccl Transcriptional repressor NULL 
AW917738 I EST 349042 INULL INULL INULL | 
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3.3.2 Verification of gene expression by quantitative RT-PCR 
To verify the gene expression profiles of the microarray, eight cancer related 
genes were selected for confirmation by RT-PCR. The expressions of these genes 
in rat MNNG induced tumors and celecoxib treated tumors were checked by 
quantitative RT-PCR. These genes include Bcl2-antagonist/killer 1 (Bakl), Acidic 
calponin 3 (Cm3), Janus protein tyrosine kinase 1 (JakJ), Leucine zipper protein 
1 {Luzpl), Aquaporin 7 (AqpT), Solute carrier family 6 member 4 (Slc6a4), DNA 
topoisomerase IIB {Top2b) and Murine thymoma viral oncogene homolog 1 
{Aktl). The first four were found to be up-regulated in celecoxib-treated tumors 
whereas the latter four were found to be down-regulated in celecoxib-treated 
tumors. 
Among the four up-regulated genes, Bakl is a proapoptotic protein which 
involves in the apoptosis pathway [94, 95]. Cm3 has been shown to inhibit 
metastasis of melanoma and adenocarcinoma cells by stabilizing the actin 
cytoskeleton [96]. Jakl is the major component of Jak/Stat signaling pathway. 
This pathway is well known to promote cell proliferation, survival and cell fate 
determination[97]. Luzpl is a DNA binding protein, which has been shown to 
induce apoptosis[98]. 
- 5 5 -
For the genes down-regulated in celecoxib treated tumors, Aqp7 is a major route 
to uptake arsenite, which is a well documented carcinogen [99, 100]. Slc6a4 is a 
serotonin transporter and helps the cells to uptake 5-hydroxytryptamine, which in 
turn induce cell proliferation[101]. Top2b is a nuclear enzyme that alters the 
topology o f DNA. It is widely expressed in proliferating tissues[102]. Aktl plays 
important roles in various cell survival pathways, it is believed to be largely 
involved in the mechanisms of the prevention of gastric cancer[103]. 
The RT-PCR results are shown in Figures 7-14. For the four up-regulated genes 
selected from microarray analysis, the expressions of Jakl were significantly 
increased in celecoxib treated tumors (p < 0.05). The other three genes, Bakl, 
Cnn3 and Luzpl, had a small and non-significant increase in expressions in 
celecoxib treated group. 
Four down-regulated genes were selected from microarray analysis (Figure 7-10)， 
the expression of Aktl was significantly inhibited in celecoxib treated tumors {p < 
0.05). There was a mild but non-significant decrease in the expressions of Aqp7, 
Slc6a4 and Top2b in celecoxib treated tumors. 











































































































































































































































































































































































































































































































































































































































































































































































3.3.3 Confirmation of the gene expression profiles in human by quantitative 
RT-PCR 
To further verify the role of these selected genes {Bakl, Cnn3, Jakl, Luzpl, Aqp7, 
Slc6a4, Top2b and Aktl) in human gastric epithelium, we determined the 
expression level of these selected genes in human gastric epithelial cancer cell 
line M K N 45 after treatment with celecoxib. 
The gene expressions levels were analyzed by quantitative RT-PCR. The results 
were shown in Figures 15-22. The same eight genes {Bakl, Cnn3, Jakl, Luzpl, 
Aqp7, Slc6a4, Top2b and Aktl) that were described in the previous section were 
examined. The effects of celecoxib treatment on the four up-regulated genes 
selected from microarray analysis were shown in Figures 15-18. There was a 
dose-dependent increase in expressions of Jakl and Luzpl after treatment with 
celecoxib. On the other hand, there was no significant alteration in Bakl and 
Cnn3 levels with celecoxib treatment. 
Four down-regulated genes {Aqp7, Slc6a4, Top2b and Aktl) were selected from 
microarray analysis (Figure 19-22). The expression of Aktl decreased when 
treated with 10 |_iM，20 |JM, 50 | iM and 100 |_iM celecoxib, which were consistent 
- 5 9 -
with the microarray analysis. However, there was no significant alteration in the 
other three genes with celecoxib treatment. 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We first determined the gene expression profiles of MNNG induced gastric 
tumors (T) and its adjacent normal (N) (group A). By using a stricter criterion of 
20-fold changes, 5 and 39 genes were up- and down-regulated, respectively. There 
are more genes being down-regulated than up -regulated in tumors, which are 
different from the results of Abe et al[59]. Abe found that 50 and 25 genes were 
found to be up- and down-regulated by 20-fold, respectively. The difference 
between our study and Abe's study may be due to the usage of different 
microarray chips. Abe et al used GeneChip Rat Genome U34A arrays, which 
contained 6,000 probe sets of known rat genes and 2,000 probe sets of rat ESTs 
(Affymetrix, Santa Clara, CA, USA) while we used UniSet Rat I Bioarray 
(Amersham, Piscataway, NJ, USA) with 10,000 probes. 
To determine the genes responsible for the chemopreventive effects of celecoxib 
on gastric cancer development, we compared the gene expression profiles of the 
two groups (MNNG and celecoxib). When combining the four groups of 
microarray data, there are two other possible expression trends that are not 
included in the analysis due to logical error (i.e. CT>T>CN>N and 
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N〉CN>T〉CT). In the CT>T>CN>N trend, it would be strange to see tumor 
suppressor genes have even lower expressions in group N than group T even 
though some genes might be up-regulated in group CT as compared to group T. 
For similar reason, the N>CN>T>CT trend is also rejected since it is 
inappropriate to have oncogene expressions higher in group N than in group T. 
Hence, only trends CN>N>CT>T and T>CT>N>CN were included in further 
analysis. 
The expressions of the eight selected genes in rat MNNG induced tumors and 
celecoxib treated tumors were verified by quantitative RT-PCR. Those expression 
patterns between microarray analysis and RT-PCR were consistent. Among those 
eight genes, only the changes in Jakl and Aktl were confirmed by RT-PCR. For 
the other six genes, consistent expression patterns as in microarray were obtained 
but the difference was not statistically significant. 
Although the genes expressions pattern between microarray and RT-PCR were 
consistent, the sensitivity of microarray was higher than RT-PCR. The microarray 
system had higher sensitivity because there were more amplification steps. In 
microarray system, RNA is transcripted into cDNA. Then the cDNA are reverse 
- 6 4 -
transcripted back into RNA and hybridized onto the chips. On the other hand, in 
the RT-PCR system, RNA is transcripted into cDNA and amplified by polymerase 
reaction. As there are more amplification steps in microarray system, the detection 
by RT-PCR is less sensitive. 
In addition to examining the gene expression in rat stomach tissues, we also 
determined the expression profiles of these genes in human stomach. The same 
eight genes (Bakl’ Cnn3, Jakl, Luzpl, Aqp7, Slc6a4, Top2b and Aktl) that were 
described previously section were examined. The expressions of Jakl’ Luzpl and 
Aktl were consistent with the microarray analysis. There was a dose-dependent 
increase in expressions of Jakl and Luzpl after treatment with celecoxib whereas 
the expression of Aktl decreased with celecoxib. 
Jakl has been shown to modulate activation of Ras-Raf-Map kinase pathways, 
which are essential and sufficient in cell proliferation[104]. Furthermore, Jakl has 
been also implicated in malignant transformation of normal cells by Abl, which is 
an oncogene derived from the Abl family of proteins[105]. Moreover, 
p55-dependent apoptosis is shown to be inhibited by Jakl[\06]. Jakl is essential 
for signal transduction as demonstrated for cells derived from Jakl knock-out 
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mice. Jakl knock-out mice are midget at birth, failed to nurse, and died 
perinatally[107]. 
The another significantly verified gene Aktl were found to be down-regulated in 
four out of five rat MNNG-induced gastric tumors by Abe[59]. Aktl is an 
important regulator of various cell survival pathways. Aktl was down-regulated in 
rat hepatoma cells[108]. The activated Aktl can phosphorylate several proteins 
including Bcl2-antagomst of cell death {Bad), Forkhead family of transcription 
factors, IkappaB kinase family members (IKKs) and Caspase 9. Aktl can 
phosphorylate Bad at Serine-112 and Serine-136 sites. Phosphorylation of either 
of these sites causes Bad to dissociate from BcI-Xl and to associate with 
cytoplasmic 14-3-3 proteins, which may protect Bad from its targets at the 
mitochondria. Thus phosphorylation of Bad inactivates its ability to cause cell 
death and promotes cell survival[109]. Forkhead family members bind to 
promoters of some genes such as Fas Iigaud and activate their transcriptions, 
which wi l l cause cell death. However, activated Aktl can phosphorylate Forkhead 
family members and keep them in cytoplasm, which can stop the transcriptions 
and promote cell survival[110]. IKKs is another target of Aktl. Akt has been 
shown to phosphorylate and activate IKK a at Thronine-2[ l l l ] . Activated IKKs 
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can promote NF-kappaB pathway, which can enhance cell survival through some 
genes such as caspaseinhibitors c-IAPl and c-IAP2[\\2\. Caspase 9 is regulated 
by Akt also. Akt can inhibits caspase 9 through phosphorylation at 
Serine-196[ 113]. Thus apoptosis is suppressed as well. 
The other five genes were not altered significantly when treated with celecoxib in 
human gastric epithelial cells. The expression discrepancies between rat tissues 
and human cancer cell lines may be due to the difference in genetic components. 
As the genetic background of rat tumor tissues and human gastric epithelial cell 
lines are dissimilar, genes in different models may have various responses to 
celecoxib. 
In conclusion, we have identified possible pathways related to cancer prevention 
by celecoxib in rat gastric tumor and verified it in human. Among various genes 
found to be altered by celecoxib, the Aktl and Jakl appear to play an instrumental 
role. 
- 6 7 -
Chapter 4 
Effects of celecoxib on Akt pathway in gastric cancer cells 
4.1 Introduction 
In our previous gene expression microarray study, the expression of Murine 
thymoma viral oncogene homolog 1 (Aktl) gene was found to be down-regulated 
in gastric tumors of rats treated with celecoxib. The expression of Aktl was 
lowered in celecoxib treated tumors as well as adjacent normal tissues. Moreover, 
the reduced expression of Aktl was confirmed by RT-PCR in human gastric 
cancer cells after treatment with celecoxib. 
The Akt gene plays important roles in various cell survival pathways leading to 
apoptosis and survival (Figure 23). Stimuli, such as insulin and various growth 
factors, mediate intracellular signaling through ligation of transmembrane 
receptors. Activation of these transmembrane receptors results in the recruitment 
of phosphoinositide-3-kinase (PI3K) to the inner surface of the plasma membrane. 
Once localized to the plasma membrane, PI3K generates phosphatidylinositol 
3,4,5 trisphosphate (PIP3) by transferring a phosphate from ATP to 
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phosphatidylinositol 3,4 bisphosphate (PIP2)[114]. 
The phosphorylation process of PI3K is counteracted by phosphatase and tensin 
homolog (PTEN). Normally, PTEN exists in a predominantly phosphorylated 
state. There are three phosphorylation residues in PTEN: Serine-380, 
Threoniiie-382, and Threonine-383[115]. The presence of the phosphorylated 
residues are important for PTEN stability[116]. Some reports suggest that PTEN 
activates itself through autodephosphorylation and then exerts the counteracting 
effect against PI3K[115]. 
PI3K-generated PIP3 activates 3-phosphoinositide-dependent protein kinase-1 
(PDKl) by phosphorylation. There are several phosphorylation sites on PDKl : 
Serine-25, Serine-241, Serine-393, Tyrosine-373, Tyrosine-376, Serine-396 and 
Serine-410. Among these phosphorylated residues, only the phosphorylation of 
Serine-241 is essential for PDKl activity]： 117]. 
Phosphorylated PDKl activates Akt by phosphorylation. There are two 
phosphorylation sites on Akt: Threonine-308 and Serine-473. Similar to PDKl , 
the phosphorylation of only one residue, Serine-473 is essential for Akt 
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activity[118]. 
Several downstream components of Akt pathway have been identified. One of the 
well known components is caspase 9. Akt inhibits pro-caspase 9 by 
phosphorylation Serine-196. In normal case, pro-caspase 9 is cleaved and caspase 
9 is generated, which can cause apoptosis. However, i f the pro-caspase 9 is 
phosphorylated, it cannot be cut down resulting in no caspase 9 formed. As a 
result, cell survival is triggered (Figure 24) [113]. Another two initiator caspases 
(caspase 2 and caspase 8) are also inactivated by phosphorylation. They are 
inhibited by calcium/calmodulin-dependent protein kinase I I (CaMKII) and 
mitogen-activated protein kinase (MAPK) respectively [119, 120]. 
While Akt may play an instrumental role on the chemoprevention of gastric 
cancer, we determined the effect of celecoxib treatment on expression of different 
mediators of the Akt pathway in gastric cancer cells. 
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Figure 23. Akt pathway 
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Figure 24. Phosphorylation of pro-caspase 9 
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4.2 Material and methods 
4.2.1 Protein extraction 
MKN45 cells were treated with various concentrations of celecoxib (10-200uM) 
for 24 hours. After the drug treatment, cells were washed by cold PBS twice and 
collected by cell scrapper. Cells were collected as pellets by centrifuging at 1,100 
rpm for 5 min. The pellets were lysed by CytoBuster protein extraction buffer 
(Novagen, Madison, WI, USA) and lOOx protease inhibitor (Amersham 
Biosciences, Piscataway, NJ, USA) for 30 min on ice. The cell lysates were 
centrifuged at 12,000 rpm for 20 min at 4 °C. The supernatant was collected, 
aliquoted in 0.5 eppendorf tubes and stored at -80°C. 
4.2.2 Western blotting 
Concentrations of the protein samples were quantified by using the Bradford Dc 
protein assay kit (Biorad, Hercules, CA, USA). Bovine serum albumin (Promega, 
Madison, WI, USA) was used as a standard for the assay. The concentrations of 
the protein samples were measured by 96-well plate reader (Rainbow Spectra, 
Tecan, Switzerland) at absorbance of 700 nm wavelength. 25 \ig protein extracts 
were denatured by 4x loading dye containing 350 m M Tris-HCl pH 6.8，10% (w/v) 
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SDS, 30% (v/v) glycerol, 10% (v/v) mercaptoethanol, 0.012% (w/v) bromophenol 
blue (All , except SDS, were purchased from Sigma, St Louis, MO, USA). 
Samples were heated at 95°C for 10 min. The samples were electrophoresed 
through 12.5% SDS-polyacrylamide gel at 120V for 2 hours. Broad range 
prestained SDS-PAGE standards (Biorad, Hercules, CA, USA) was used as 
protein marker. 
Proteins in the separating gel were transferred to PVDF membranes by 
electroblotting at lOOV for 1.5 hours at 4°C. After the transfer process, 
membranes were washed with TBS (20mM Tris-HCl, 137mM NaCl, pH 7.5) in 
room temperature for 5 min. The membranes were then incubated with blocking 
solution [5% (w/v) non-fat milk in TBS-T (20mM Tris-HCl, 137mM NaCl, 0.1% 
Tween 20, pH 7.5)] at room temperature for 1 hour, and washed with TBS-T in 
room temperature for 5 min thrice. Primary antibodies against phospho-Akt 
(Ser473), phospho-PDK-1 (Ser241), phospho-PTEN (Ser380), or caspase-9 (all in 
1:2000 dilutions; Cell Signaling, Beverly, MA, USA) were probed with the 
membranes in blocking solution at 4°C overnight on a shaker. Monoclonal anti-P 
actin antibody was used as a control. After the incubation with primary antibodies, 
the membranes were washed with TBS-T in room temperature for 5 min thrice. 
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Secondary antibodies conjugated with horseradish peroxidase (1:5000, Cell 
Signaling, Beverly, M A , USA) were incubated with the membranes in blocking 
buffer for 1 hour in room temperature on a shaker. After the secondary antibody 
incubation, the membranes were washed with TBS-T in room temp for 5 min 
thrice. Then the membranes were developed with Super Signal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL，USA). Immunodetection were 
recorded by HyperFilms (Amersham Bioscience, Buckinghamshire, UK). 
4.3 Results 
4.3.1 Expression of the Akt pathway after treatment with celecoxib 
Human gastric epithelial cancer cell line M K N 45 was incubated with various 
concentrations of celecoxib for 24 hours. Cells were harvested and total protein 
was extracted for western blot analysis. 
From the western blot analysis, the protein expression of Phospho-Akt remained 
unchanged when treated with low dose celecoxib. The expression dropped slightly 
when treated with 100 \ iM celecoxib and was completely blocked with 200 j iM 
celecoxib (Figure 25). 
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The protein expression of Phospho-PDKl showed similar trend as the 
Phospho-Akt. The expression of Phospho-PDKl remained unchanged when 
treated with 10 |j-M or 50 | iM celecoxib. By raising the celecoxib concentration to 
100 | iM, the expression dropped significantly. When treated with 200 |_iM 
celecoxib, the expression further decreased (Figure 25). 
The Phospho-PTEN is an upstream regulator of this pathway, which controls the 
expression of Phospho-Akt and Phospho-PDKl. By treating the MKN45 cells 
with various concentration of celecoxib, the expression of Phospho-PTEN 
remained unchanged (Figure 25). Our findings support that celecoxib inhibited 
the production of Phospho-Akt and Phospho-PDKl but not Phospho-PTEN 
production. 
As Akt is a major mediator that regulates multiple cell survival pathways, three 
downstream components in the Akt pathway (caspase 2, caspase 8 and caspase 9) 
were selected for examination. 
The expression levels of total caspase 2，total caspase 8 and total caspase 9 were 
shown in Figure 26. There was a dose-dependent increase in total caspase 8 
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expression with celecoxib treatment. When treated with 200 | iM celecoxib, the 
expression level of total caspase 8 was about two fold of the untreated cells. On 
the other hand, there was no significant alteration in expression levels of total 
caspase 2 and total caspase 9. 
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Control lOuM 50uM lOOuM 200uM 
p h o s p h o - A k t nmnn i i i i ^^n^mi i i i i ^m in 
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Phospho-PTEN 
Figure 25. Expression of Akt and its upper components in the pathway when 
treated with various concentration of celecoxib. 
Control lOuM 20uM SOuM lOOuM 200uM 
0,814 0.717 1.051 0.902 0.81 0.875 
0.589 0.751 0.802 1.067 0.903 丨.032 
^ ^ ^ ^ i ^ K j j L ^ ^ ^ ^ ^ ^ ^^^^^^ 
c a s p a s e s ^ g ^ f M 請 ^ f ^ f p f ^ 
1.038 0.932 1.043 1.188 1.027 1.247 
‘ a - _ M > m m m m _ 
Figure 26. Induction of the expressions of the downstream mediators in the Akt 
pathway when treated with various concentration of celecoxib. The numbers 
above each films show the relative band intensities. 
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4.4 Discussion 
In our gene expression microarray study, the expression of Murine thymoma viral 
oncogene homolog 1 (Aktl) gene was found to be down-regulated in gastric 
tumors of rats and human gastric epithelial cells after treatment with celecoxib. To 
investigate the expression level of Akt and its relative components in the pathway, 
human gastric epithelial cancer cell line M K N 45 was incubated with various 
concentrations of celecoxib. As the active form of Akt is phosphorylated[ 118], we 
measured the activity of Akt protein by using anti-phospho-Akt as primary 
antibody in western blotting. The protein expression of Phospho-Akt remained 
unchanged when treated with low dose celecoxib. The expression dropped slightly 
when treated with 100 | iM celecoxib and was completely blocked with 200 |j.M 
celecoxib. The result showed that the activity of Akt decreased in a dose 
dependent manner as the concentration of celecoxib increased. 
As Akt is phosphorylated by 3-phosphoinositide- dependent protein kinase-1 
(PDKl) , the protein expression of PDKl was measured. Similar to Akt, the active 
form of PDKl is also phosphorylated[117]. The expression level of PDKl was 
similar to that of Akt. The expression of Phospho-PDKl remained unchanged 
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when treated with low dose celecoxib. By raising the celecoxib concentration at 
100 \xM, the expression dropped significantly. As a result, the activity of PDKl 
decreased in a dose dependent manner as the concentration of celecoxib 
increased. 
When we keep tracing upward along the pathway, a protein called phosphatase 
and tensin homolog (PTEN) regulates the concentration of PI3K[115]. Unlike 
Phospho-Akt and Phospho-PDKl, the expression of Phospho-PTEN remained 
unchanged in various concentration of celecoxib. 
There was a dose-dependent increase in total caspase 8 expression with celecoxib 
treatment. The protein expression level of total caspase 8 was in opposite manner 
to that of Phospho-Akt and Phospho-PDKl when treating with celecoxib. On the 
other hand, there was no significant alteration in expression levels of total caspase 
2 and total caspase 9. The induction of protein expression of caspase 8 was shown 
to be greater than that of caspase 9 in our results. This finding may be accounted 
by the existence of other pathways that regulates the expression of caspase 8. 
Caspase 8 was shown to be suppressed through phosphorylation at Serine-364 by 
active phosphorylated p3 8-mitogen-activated protein kinase (MAPK)[120]. 
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However, celecoxib could decrease the phosphorylation state of p38-MAPK[121]. 
Thus less caspase 8 was phosphorylated and it might explain the significant 
induction in protein expression of total caspase 8 in our results. 
Apoptosis protease activator protein-1 (APAF-1) is an essential component of 
apoptosome, which can catalyze procaspase-9 into active caspase 9[122]. Zanon 
et al used APAF-1 expressing melanoma cell line to show that the induction of 
caspase 8 was greater than that of caspase 9 by celecoxib [123]. Similar results 
were obtained by using APAF-1 deficient melanoma cell line. However, in 
Zanon,s study, the induction of caspase 2 was apparently stronger than that of 
caspase 8 and caspase 9，which was different from our results. The induction of 
caspase 2 was higher in APAF-1 + than in APAF-l" cell line. 
On the other study, Jendrossek et al examined the protein expressions of caspase 8 
and caspase 9 in response to celecoxib in Jurkat T-lymphoma cells[124]. Similar 
to our results, Jendrossek showed that the induction effect of caspase 8 was higher 
than caspase 9 upon celecoxib treatment. It seems that although caspase 9 is 
proven to be the main downstream target of Akt, the interaction between Akt and 
caspase 8 is greater than that between Akt and caspase 9. On the other hand, there 
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may also be differential responses to celecoxib in different tissue types that 
account for the discrepant results. 
In conclusion, we found that the specific COX-2 inhibitor, celecoxib, 
down-regulate phosphorylated Akt and phosphorylated PDKl but not 
phosphorylated PTEN in gastric cancer cells that may play a major role on gastric 
cancer prevention. 
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Chapter 5 
Conclusion 
Traditional NSAIDs inhibit both COX-1 and COX-2 and there are more side 
effects associated with gastrointestinal damage due to COX-1 inhibition[125]. 
Therefore, celecoxib, a COX-2 selective inhibitor, can retain efficacy with less 
adverse side effects within the gastrointestinal tract. Celecoxib has been approved 
for osteoarthritis and rheumatoid arthritis treatment. We have demonstrated the 
chemopreventive effect of celecoxib on gastric carcinogenesis in rats. In addition, 
celecoxib was shown to inhibit the growth of human gastric cancer cell line M K N 
45 in a concentration-dependent manner. As a result, celecoxib is effective in 
preventing gastric cancer and may be tried on human for gastric cancer prevention. 
Our results may also suggest that it may be applied as treatment for human gastric 
cancer as well. 
From our microarray analysis, celecoxib was shown to alter numerous gene 
expressions in gastric tissues. Those altered genes may play important roles in 
other pathway leading to gastric cancer prevention and explain the complications 
of celecoxib. As a result, further characterization and comparison of the genes 
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expression profiles are needed to discover the potent functions of celecoxib in 
gastric cancer prevention. 
Based on our results and previous reports which suggest that NSAIDs exert their 
anti-neoplastic effects through COX independent pathway [40-42], it is 
reasonable to speculate that the chemopreventive effect of celecoxib is mediated 
by both COX- and non-COX dependent pathways. In particular, the 
COX-independent Akt pathway may play an important role. By using western 
blotting, we have demonstrated that celecoxib suppressed Akt phosphorylation 
resulting in augmentation of caspase 8 expression and enhances apoptosis. 
Although celecoxib has fewer GI side effects than non-selective NSAIDs, 
long-term use of celecoxib is associated with an increase in cardiovascular risk. 
Thus, other ways to alter the Akt pathway may be considered as alternative 
chemopreventive agent against gastric cancer to minimize the side effects of 
COX-2 inhibitor. For examples, wortmannin and LY294002 are specific 
inhibitors of PI3K, which have been has been shown to block PI3 
kinase-dependent Akt phosphorylation and kinase activity[126, 127]. 
In the lower part of the Akt pathway, the protein expression of caspase 8, rather 
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than caspase 9, was significantly induced upon celecoxib treatment. The 
inductions of caspase proteins revealed that celecoxib suppresses the growth of 
gastric cancer by enhancing the apoptosis pathway. Notably, our findings may 
suggest a greater interaction between Akt and caspase 8. 
Apart from Akt pathway, our microarray results showed that Jakl was also altered 
by celecoxib. There is no study suggesting any association between celecoxib and 
Jakl pathway. As Jakl is the major component of Jak/Stat signaling pathway, 
which is well known to promote cell proliferation, survival and cell fate 
determination, our results provide another possible mechanism related to gastric 
cancer chemoprevention. Further study is needed to explore the potential 
interaction of celecoxib and Jakl in gastric carcinogenesis and prevention. 
There were some limitations of these studies. The number of rats which develop 
gastric tumor in celecoxib group was low. Therefore, only very few celecoxib 
treated tumor tissues were available for microarray analysis. As a result, the 
sample size was not large enough to obtain significant results by statistical 
analysis. The second limitation is the fold change cut-off value in microarray 
analysis. In my study, genes expression fold changes among N and T larger than 
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1.5 were kept for further analysis. The fold change may be too small which can 
only show a slight significant result in biological system. However, some other 
research groups such Abe used small cut-off value also. Hence, I used small 
cut-off value in order to compare our results with other research groups. Another 
limitation is the lack of exploratory works on unknown genes. Many genes were 
unknown in the microarray slide which may play important roles in the prevention 
of gastric cancer. This study focus on know tumor related genes and may miss 
some information in studying the chemopreventive mechanism of celecoxib. 
Our results have contributed insights into the chemopreventive mechanism of 
celecoxib in gastric cancer. However, there are still questions about the 
chemopreventive mechanism of celecoxib in gastric cancer and needs for further 
studies. As the signal transduction pathways are complicated, further study may 
be necessary to explore other non-COX dependent pathways, such as Jakl. It may 
provide us with other possible mechanisms which can enrich or counteract the 
effect of Akt pathway. Furthermore, it is important to find out whether celecoxib 
interacts directly with Akt or not. Thus we may need to investigate how the 
celecoxib interfere with the phosphorylation of Akt. I f possible, we may need to 
determine other intermediate components between celecoxib and Akt such as 
- 8 5 -
PDKl . In addition, although caspase 9 is proven to be the main downstream target 
of Akt, the protein expression of caspase 8 was greater than that of caspase 9 in 
our study. As a result, we may have to further compare the relationships between 
Akt and different caspases. At last, as there are reports suggesting long-term use 
of celecoxib may increase the risk of serious cardiovascular events, it is advisable 
to identify the functional group of celecoxib which have the inhibitory functions 
but not the side effects[ 128].Therefore, celecoxib with modified structures should 
be developed to have a drug with fewer side effects. 
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